

Interim financial information

1st quarter of 2025

(Convenience Translation into English from the
Original Previously Issued in Portuguese)

Oncoclínicas do Brasil Serviços Médicos S.A.

Individual and Consolidated
Interim Financial Statements
for the Period Ended
March 31, 2025 and
Independent Auditor's Report

Deloitte Touche Tohmatsu Auditores Independentes Ltda.

(Convenience Translation into English from the Original Previously Issued in Portuguese)

REPORT ON REVIEW OF INTERIM FINANCIAL STATEMENTS

To the Shareholders, Directors and Management of
Oncoclínicas do Brasil Serviços Médicos S.A.

Introduction

We have reviewed the accompanying individual and consolidated interim financial information of Oncoclínicas do Brasil Serviços Médicos S.A. ("Company"), included in the Interim Financial Statements Form (ITR) for the period ended March 31, 2025, which comprises the balance sheet as at March 31, 2025 and the related statements of income, of comprehensive income, of changes in equity and of cash flows for the three-month period then ended, including the explanatory notes.

The Executive Board is responsible for the preparation of this individual and consolidated interim financial statements in accordance with technical pronouncement CPC 21 (R1) and international standard IAS 34 - Interim Financial Reporting, issued by the International Accounting Standards Board - IASB, as well as for the presentation of such information in accordance with the standards issued by the Brazilian Securities and Exchange Commission (CVM), applicable to the preparation of Interim Financial Information (ITR). Our responsibility is to express a conclusion on this interim financial information based on our review.

Scope of review

We conducted our review in accordance with Brazilian and international standards on review of interim financial information (NBC TR 2410 and ISRE 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity, respectively). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the standards on auditing and, consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion on the individual and consolidated interim financial information

Based on our review, nothing has come to our attention that causes us to believe that the individual and consolidated interim financial information included in the ITR referred to above was not prepared, in all material respects, in accordance with technical pronouncement CPC 21 (R1) and international standard IAS 34, applicable to the preparation of ITR, and presented in accordance with the standards issued by the CVM.

Other matters

Statements of value added

The interim financial statements referred to above includes the individual and consolidated statements of value added (DVA) for the three-month period ended March 31, 2025, prepared under the responsibility of the Company's Executive Board and presented as supplemental information for international standard IAS 34 purposes. These statements were subject to the review procedures performed together with the review of the Interim Financial Information (ITR) to reach a conclusion on whether they are reconciled with the interim financial information and the accounting records, as applicable, and if their form and content are consistent with the criteria set forth in technical pronouncement CPC 09 - Statement of Value Added. Based on our review, nothing has come to our attention that causes us to believe that these statements of value added were not prepared, in all material respects, in accordance with the criteria defined in such technical pronouncement and consistently with the individual and consolidated interim financial information taken as a whole.

Convenience translation

The accompanying individual and consolidated interim financial information has been translated into English for the convenience of readers outside Brazil.

São Paulo, May 15, 2025



DELOITTE TOUCHE TOHMATSU
Auditores Independentes Ltda.



Daniel de Carvalho Primo
Engagement Partner

ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.

BALANCE SHEETS AS OF MARCH 31, 2025 AND DECEMBER 31, 2024
(In thousands of reais - R\$)

ASSETS	Note	Parent Company		Consolidated		LIABILITIES AND SHAREHOLDERS' EQUITY	Note	Parent Company		Consolidated	
		03/31/2025	12/31/2024	03/31/2025	12/31/2024			03/31/2025	12/31/2024	03/31/2025	12/31/2024
CURRENT ASSETS											
Cash and cash equivalents	4	171.512	228.812	550.519	550.744	CURRENT LIABILITIES					
Securities and financial assets	5	790.605	937.548	1.088.317	1.337.630	Suppliers	14	189.554	154.966	994.297	1.019.530
Derivative financial instruments	28	16.543	32.191	16.543	32.191	Loans and financing	15	357.484	425.903	435.864	522.860
Trade accounts receivable	6	265.399	288.180	1.987.845	2.049.014	Derivative financial instruments	28	-	124	-	124
Inventories	7	39.557	53.642	190.128	225.235	Debentures	16	84.906	37.277	296.495	233.272
Recoverable taxes	8	56.477	101.486	190.811	314.099	Social charges	17	67.215	67.001	157.698	155.182
Dividends receivable	29.2	98.159	102.004	-	-	Tax liabilities	18	17.990	38.197	95.552	177.829
Other assets	9	61.371	51.147	178.561	151.871	Income tax and social contribution	27	-	-	40.871	54.753
Total current assets		1.499.623	1.795.010	4.202.724	4.660.784	Accounts payable for acquisitions	19	12.236	21.481	148.429	85.494
						Dividends payable	29.5	4.704	-	34.278	37.134
						Related parties	29.4	-	35.785	-	35.785
						Lease liabilities	13.2	15.130	13.077	52.686	57.825
						Other liabilities	20	22.533	24.652	71.495	73.418
						Total current liabilities		771.752	818.463	2.327.665	2.453.206
NON-CURRENT ASSETS											
Securities and financial assets	5	2.111	102.484	19.578	129.921	NON-CURRENT LIABILITIES					
Derivative financial instruments	28	9.307	7.016	9.307	7.016	Loans and financing	15	1.507.077	1.546.636	1.897.858	1.946.239
Trade accounts receivable	6	170.153	153.360	505.359	385.580	Derivative financial instruments	28	90.829	106.922	90.829	106.922
Judicial deposits	21	22.399	22.571	70.325	66.165	Debentures	16	1.727.929	1.727.150	2.196.270	2.214.836
Deferred income tax and social contribution	27	298.859	288.192	545.093	508.090	Social charges	17	10.227	12.951	10.227	12.951
Related parties	29	1.101.247	1.095.803	20.513	20.664	Tax liabilities	18	6.613	7.737	37.132	52.551
Advances for future capital increase	29.3	74.692	87.239	-	-	Deferred income tax and social contribution	27	-	-	45.767	41.186
Other assets	9	198.180	197.972	276.563	294.804	Provision for tax, labor and civil risks	21	9.874	10.218	49.304	50.907
						Accounts payable for acquisitions	19	71.257	80.892	267.761	347.480
Investments in subsidiaries and associated companies	10	3.821.683	3.781.915	51.578	42.960	Related parties	29.4	470.097	502.631	6.670	7.830
Property, plant and equipment	11	135.025	126.285	811.242	822.525	Advances for future capital increase	29.6	-	-	6.334	6.334
Intangible assets	12	393.144	390.314	3.735.393	3.750.517	Lease liabilities	13.2	43.007	38.249	579.176	503.367
Right-of-use	13.1	52.122	45.760	578.137	513.306	Provision for loss on investment in subsidiaries	10	30.039	46.902	-	-
Total non-current assets		6.278.922	6.298.911	6.623.088	6.541.548	Other liabilities	20	44.072	48.820	67.968	76.098
						Total non-current liabilities		4.011.021	4.129.108	5.255.296	5.366.701
SHAREHOLDERS' EQUITY											
							22				
						Capital		3.147.024	3.147.024	3.147.024	3.147.024
						Expenditures with public offering of shares		(121.760)	(121.760)	(121.760)	(121.760)
						Treasury shares		(94.468)	(94.468)	(94.468)	(94.468)
						Capital reserve		1.662.382	1.659.018	1.662.382	1.659.018
						Equity valuation adjustment		7.724	11.406	7.724	11.406
						Transaction among partners		(747.572)	(743.806)	(747.572)	(743.806)
						Accumulated losses		(857.558)	(711.064)	(857.558)	(711.064)
						Shareholders' equity attributed to non-controlling interest					
						parent company's shareholders		2.995.772	3.146.350	2.995.772	3.146.350
						Non-controlling shareholders		-	-	247.079	236.075
						Total shareholders' equity		2.995.772	3.146.350	3.242.851	3.382.425
TOTAL ASSETS		7.778.545	8.093.921	10.825.812	11.202.332	TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		7.778.545	8.093.921	10.825.812	11.202.332

See the accompanying notes to the interim financial information.

ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.

STATEMENTS OF INCOME
FOR THE YEARS ENDED MARCH 31, 2025 AND MARCH 31, 2024
(In thousands of reais, except for earning [loss] per share)

	Note	Parent Company		Consolidated	
		01/01/2025-0 3/31/2025	01/01/2024-0 3/31/2024	01/01/2025-0 3/31/2025	01/01/2024-0 3/31/2024
NET REVENUE	23	255.664	241.008	1.493.156	1.458.666
Cost of services	24	(192.442)	(116.200)	(1.080.912)	(976.386)
GROSS INCOME		63.222	124.808	412.244	482.280
OPERATING REVENUES (EXPENSES)					
General and administrative expenses	24	(72.546)	(46.404)	(358.844)	(316.967)
Other operating revenues (expenses), net	24	(15.605)	(2.626)	(11.777)	1.483
Equity in net income of subsidiaries	10	(33.938)	(4.452)	14.538	(1)
OPERATING INCOME (LOSS) BEFORE FINANCIAL INCOME (LOSS)		(58.867)	71.326	56.161	166.795
FINANCIAL INCOME (LOSS)					
Financial revenues	25	114.895	19.350	108.767	19.565
Financial expenses	25	(193.212)	(136.107)	(256.935)	(211.463)
		(78.317)	(116.757)	(148.168)	(191.898)
OPERATING INCOME (LOSS) AND BEFORE INCOME TAX AND SOCIAL CONTRIBUTION		(137.184)	(45.431)	(92.007)	(25.103)
INCOME TAX AND SOCIAL CONTRIBUTION					
Current	27	(18.106)	(4)	(67.140)	(34.852)
Deferred	27	8.796	55.027	27.173	79.544
NET INCOME (LOSS) FOR THE PERIOD		(146.494)	9.592	(131.974)	19.589
ATTRIBUTED TO					
Controlling shareholders				(146.494)	9.592
Non-controlling shareholders				14.520	9.997
				(131.974)	19.589
EARNINGS (LOSSES) PER SHARE					
Basic (cents per share - in R\$)	26	(0,2511)	0,0110		
Diluted (cents per share - in R\$)	26	(0,2511)	0,0107		

See the accompanying notes to the interim financial information.

ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.

**STATEMENTS OF COMPREHENSIVE INCOME
FOR THE YEARS ENDED MARCH 31, 2025 AND MARCH 31, 2024
(In thousands of reais - R\$)**

NET INCOME (LOSS) FOR THE PERIOD

Items that may be reclassified in the statement of income:
Exchange-rate change in the translation of foreign operations

TOTAL COMPREHENSIVE INCOME FOR THE PERIOD

ATTRIBUTABLE TO

Controlling shareholders
Non-controlling shareholders

Parent Company			Consolidated
01/01/2025–0 3/31/2025	01/01/2024–0 3/31/2024	01/01/2025–0 3/31/2025	01/01/2024– 03/31/2024
(146.494)	9.592	(131.974)	19.589
(3.682)	(31)	(3.682)	(31)
(150.176)	9.561	(135.656)	19.558
-	-	(150.176)	9.561
-	-	14.520	9.997
-	-	(135.656)	19.558

See the accompanying notes to the interim financial information.

ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.

**STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (PARENT COMPANY AND CONSOLIDATED)
FOR THE YEARS ENDED MARCH 31, 2025 AND MARCH 31, 2024
(In thousands of reais - R\$)**

		Capital									
	Note	Subscribed	Expenditures with public offering of shares	Treasury shares	Capital reserve	Equity valuation adjustment	Transaction among partners	Accumulated losses	Attributed to controlling shareholders	Non-controlling interest	Total shareholders' equity
BALANCES AT DECEMBER 31, 2023		2.454.716	(116.069)	(103.703)	840.679	13.285	(722.808)	(64.874)	2.301.226	378.145	2.679.371
Net income for the period		-	-	-	-	-	-	9.592	9.592	9.997	19.589
Dividends paid to non-controlling shareholders		-	-	-	-	-	-	-	-	(350)	(350)
Exchange-rate change in the translation of foreign operations		-	-	-	-	(31)	-	-	(31)	-	(31)
Share-based payment		-	-	101	4.805	-	-	-	4.906	-	4.906
Acquisition of equity interest with non-controlling shareholders		-	-	-	-	-	(14.931)	-	(14.931)	(13.033)	(27.964)
Transactions among partners		-	-	-	-	-	(277)	-	(277)	(140)	(417)
BALANCES AT MARCH 31, 2024		2.454.716	(116.069)	(103.602)	845.484	13.254	(738.016)	(55.282)	2.300.485	374.619	2.675.104
BALANCES AT DECEMBER 31, 2024		3.147.024	(121.760)	(94.468)	1.659.018	11.406	(743.806)	(711.064)	3.146.350	236.075	3.382.425
Loss for the period		-	-	-	-	-	-	(146.494)	(146.494)	14.520	(131.974)
Dividends paid to non-controlling shareholders		-	-	-	-	-	-	-	-	(5.335)	(5.335)
Exchange-rate change in the translation of foreign operations		-	-	-	-	(3.682)	-	-	(3.682)	373	(3.309)
Share-based payment	22.c)	-	-	-	3.364	-	-	-	3.364	-	3.364
Acquisition of equity interest with non-controlling shareholders	22.d)	-	-	-	-	-	2.527	-	2.527	(2.527)	-
Transactions among partners	22.e)	-	-	-	-	-	(6.293)	-	(6.293)	3.973	(2.320)
BALANCES AT MARCH 31, 2025		3.147.024	(121.760)	(94.468)	1.662.382	7.724	(747.572)	(857.558)	2.995.772	247.079	3.242.851
		-	-	-	-	-	-	-	-	-	-

See the accompanying notes to the interim financial information.

ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.

**STATEMENTS OF CASH FLOW
FOR THE YEARS ENDED MARCH 31, 2025 AND MARCH 31, 2024
(In thousands of reais - R\$)**

Note	Parent Company		Consolidated	
	01/01/2025-03/ 31/2025	01/01/2024-03/ 31/2024	01/01/2025-03/ 31/2025	01/01/2024-03/ 31/2024
CASH FLOW FROM OPERATING ACTIVITIES				
Net income (loss) for the period	(146.494)	9.592	(131.974)	19.589
Adjustments to reconcile net income for the year with net cash generated by operating activities:				
Depreciation and amortization	24	23.283	17.269	67.649
(Reversal) provision for expected credit loss and disallowances	23	4.896	3.667	61.882
Equity in net income of subsidiaries	10	33.938	4.452	1
Yield from securities		(31.149)	(102)	(272)
Interest on loans, financing, debentures and drawee risk	25	96.149	87.218	136.989
Interest from lease	25	1.640	481	9.905
Interest referring to related parties and acquisitions	25	(18.364)	(4.153)	10.397
Discounts obtained		-	(321)	-
Adjustment to present value	25	854	880	2.509
Adjustment to fair value	25	37.219	674	1.511
Expenses with share-based payments	24	4.007	5.774	5.774
Exchange-rate change	25	(1.921)	2.328	3.543
Mark-to-market - Swap	25	2.436	2.436	24.123
Deferred income tax and social contribution	27	(8.796)	(55.027)	(79.544)
Write-off of property, plant and equipment and intangible assets		-	2.034	21
Provision (reversal of provision) for tax, labor and civil risks	23	(344)	(2.946)	278
		(2.646)	97.682	263.702
Changes in operating assets and liabilities:				
Trade accounts receivable	31	1.365	(26.329)	(336.615)
Inventories		14.085	18.752	(47.848)
Recoverable taxes		45.349	(23.831)	(84.517)
Judicial deposits		172	(154)	(353)
Other assets		1.138	(16.004)	(29.444)
Suppliers		34.588	(40.019)	58.648
Tax liabilities	31	(23.533)	19.835	123.231
Social charges	31	(3.153)	1.925	9.968
Other liabilities		(13.290)	2.922	(2.238)
		56.721	(62.903)	(309.168)
Interest paid on loans, financing, debentures, leases and acquisitions	15, 16, 13 and 19	(55.745)	(38.458)	(87.590)
Income tax and social contribution paid	31	-	-	(28.157)
Net cash invested in operating activities		(1.670)	(76.865)	(133.056)
CASH FLOW FROM INVESTMENT ACTIVITIES				
Acquisitions of partnerships		-	(2.427)	(142.000)
Acquisition of property, plant and equipment and intangible assets	31	(14.495)	(23.303)	(39.448)
Advance of acquisition and partnership agreements		-	(58.232)	(99.670)
Securities		278.465	269.246	389.273
Advance for future capital increase	31	(128.221)	(52.911)	-
Capital increase		(36.623)	-	(36.623)
Related parties		25.922	(92.365)	973
Net cash invested (generated) in investment activities		125.048	42.435	(86.411)
CASH FLOW FROM FINANCING ACTIVITIES				
Funding of loans and financing and debentures	15 16	30.000	164.994	38.111
Settlement of swap	15 16	(5.296)	(7.827)	(5.296)
Amortization of loans and financing and debentures	15 16	(158.986)	(2.481)	(225.267)
Payment of acquisitions	31	(10.335)	(20.350)	(21.005)
Share redemption payment	20	-	-	(3.692)
Payment of intangible assets	20	-	(4.581)	-
Dividends paid	22.d	-	-	(5.334)
Debits with related parties		(44.487)	(128.800)	(2.722)
Payment of leased assets	13.2	(3.646)	(3.432)	(12.148)
Net cash invested by financing activities		(192.750)	(2.477)	(237.353)
The effects of exchange rate changes on the cash balance held in currencies foreign		-	-	2.245
Cash acquired in mergers	1	12.072	-	-
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		(57.300)	36.279	(225)
Cash and cash equivalents at the beginning of the year	4	228.812	41.496	550.744
Cash and cash equivalents at the end of the year	4	171.512	77.775	550.519
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		(57.300)	36.279	(225)

See the accompanying notes to the interim financial information.

STATEMENTS OF ADDED VALUE
FOR THE YEARS ENDED MARCH 31, 2025 AND MARCH 31, 2024
(In thousands of reais - R\$)

	Notes	Parent Company		Consolidated	
		01/01/2025–0	01/01/2024–0	01/01/2025–0	01/01/2024–0
		3/31/2025	3/31/2024	3/31/2025	3/31/2024
Revenues		274.320	258.016	1.604.588	1.602.775
Rendering of services	23	277.177	259.979	1.658.058	1.620.818
Revenues from construction of own assets and leasehold improvements		2.039	1.704	11.674	43.839
Provision for expected credit losses and disallowances	23	(4.896)	(3.667)	(65.144)	(61.882)
Inputs acquired from third parties		(232.091)	(129.737)	(1.165.380)	(1.024.580)
Cost of services		(191.496)	(117.864)	(936.042)	(883.630)
Materials, energy, outsourced services		(24.593)	(8.415)	(216.903)	(141.408)
Other		(16.002)	(3.458)	(12.435)	458
Gross value added		42.229	128.279	439.208	578.195
Retentions		-	-	-	-
Depreciation and amortization	24	(23.283)	(17.269)	(74.109)	(67.649)
Net added value		18.946	111.010	365.099	510.546
Added value received as transfer		80.957	14.899	123.305	19.564
Equity in net income of subsidiaries	10	(33.938)	(4.452)	14.538	(1)
Financial revenues	25	114.895	19.351	108.767	19.565
Other transfers received		-	-	-	-
Total added value		99.903	125.909	488.404	530.110
Distribution of added value		99.903	125.909	488.404	530.110
Personnel and charges		23.468	16.301	186.682	194.666
Direct remuneration		19.849	12.933	141.692	153.308
Benefits		2.978	2.768	36.313	31.958
FGTS		641	600	8.677	9.400
Taxes, rates and contributions		28.676	(37.281)	172.287	98.026
Federal		21.839	(42.899)	129.553	58.970
Municipal		6.837	5.618	42.734	39.056
Third-party capital remuneration		194.253	137.297	261.409	217.829
Financial expenses	25	193.212	136.108	256.935	211.463
Expenses with occupation		1.041	1.189	4.474	6.366
Remuneration of own capital		(146.494)	9.592	(131.974)	19.589
Dividends		-	-	-	-
Retained earnings (loss)		(146.494)	-	(146.494)	9.592
Non-controlling interest in retained earnings		-	-	14.520	9.997

8

Contents

1.	OPERATIONS	10
2.	DESCRIPTION OF SIGNIFICANT ACCOUNTING POLICIES - MATERIAL AND CLARIFYING	11
3.	NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS OF STANDARDS	12
4.	CASH AND CASH EQUIVALENTS	12
5.	SECURITIES AND OTHER FINANCIAL ASSETS	12
6.	TRADE ACCOUNTS RECEIVABLE	13
7.	INVENTORIES	14
8.	RECOVERABLE TAXES	14
9.	OTHER ASSETS	14
10.	INVESTMENTS IN SUBSIDIARIES AND ASSOCIATED COMPANIES	15
11.	PROPERTY, PLANT AND EQUIPMENT	22
12.	INTANGIBLE ASSETS	26
13.	RIGHT-OF-USE AND LEASE LIABILITIES	29
14.	SUPPLIERS	30
15.	LOANS AND FINANCING	30
16.	DEBENTURES	32
17.	SOCIAL CHARGES	33
18.	TAX LIABILITIES	33
19.	ACCOUNTS PAYABLE FOR ACQUISITIONS	34
20.	OTHER LIABILITIES	36
21.	PROVISION FOR TAX, LABOR AND CIVIL RISKS	36
22.	SHAREHOLDERS' EQUITY	38
23.	REVENUES	40
24.	COSTS AND EXPENSES BY TYPE	41
25.	FINANCIAL INCOME (LOSS)	42
26.	EARNINGS PER SHARE	43
27.	INCOME TAX AND SOCIAL CONTRIBUTION	43
28.	FINANCIAL INSTRUMENTS	46
29.	RELATED PARTIES	57
30.	INSURANCE	62
31.	TRANSACTIONS NOT AFFECTING CASH	63

ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.
NOTES TO THE INTERIM FINANCIAL STATEMENTS
FOR THE PERIOD ENDED MARCH 31, 2025
(In thousands of reais - R\$, unless otherwise indicated)

1. OPERATIONS

Oncoclínicas do Brasil Serviços Médicos S.A. ("Company", "Parent Company" or "Oncoclínicas"), headquartered in São Paulo-SP, established in 2010, is a publicly-held company since August 2021, listed on the Novo Mercado of B3 S.A., whose shares are traded under ticker symbol ONCO3. The Company and its subsidiaries (collectively "Group" or "Oncoclínicas Group") provide healthcare services, mainly focused on Oncology.

Since its establishment, the Company, in addition to providing treatment to oncology patients, has been dedicated to studying and identifying the most appropriate therapy opportunities for patients and growth trends in the industry. In essence, the patient is the center of everything, reason why Oncoclínicas Group is always looking for the most advanced treatments and the highest quality and safety levels.

Oncoclínicas' mission is to "beat the cancer".

As of March 31, 2025, the Company does not have controlling shareholder. On July 10, 2024, the capital increase was approved, as Note 23, where shareholders Josephina Fundo de Investimento em Participações Multiestratégia, Josephina II Fundo de Investimento em Participações Multiestratégia and Bruno Lemos Ferrari terminated, on said date, the shareholders' agreement of the Company, entered into on May 7, 2021, causing the Company to no longer have a controlling shareholder or defined control group.

The Oncoclínicas Group is an oncology network in Brazil composed of 149 operating units in 2025, operating in 45 cities in the specialized areas of chemotherapy, diagnostic medicine, radiotherapy, hospitals and oral drugs.

The Company's interim financial information for the first quarter ended March 31, 2025 was deliberated and authorized for issuance by the Board of Directors on May 14, 2025.

Corporate restructuring

Continuing with Oncoclínicas Group's strategy in its corporate restructuring project, which covers seeking synergy between its business areas and increasing its operational and financial efficiency, the merger and spin-off movements were carried out during the first three months of 2025, as follows:

On January 31, 2025, the Group carried out the merger of the partially spun-off net assets of Centro de Quimioterapia Oncoclínicas S.A. into Idegene Medicina Diagnóstica S.A.

On January 31, 2025, a downstream merger of Centro Mineiro de Infusões S.A. into Centro Paraibano de Oncologia S.A. was also carried out. In this transaction, Centro Paraibano de Oncologia S.A. became a direct investee of the Company. Subsequently, the merger of the partially spun-off net assets of Centro Paraibano de Oncologia S.A. into Oncobio Serviços de Saúde S.A. was carried out.

On February 28, 2025, the Company carried out the partial merger of spun-off net assets of the companies AIO - Instituto de Câncer de Brasília Ltda. and CETTRO - Centro de Tratamento Oncológico Ltda., as well as the total merger of Céu de Brasília Participações S.A.

On February 28, 2025, the partially spun off net assets of Instituto de Oncologia Kaplan S.A. were merged into Idegene Medicina Diagnóstica S.A.

Impacts on the Parent Company's balance sheet due to the merger of Céu, CETTRO, and AIO

	Céu de Brasília Participações S.A.	CETTRO - Centro de Tratamento Oncológico Ltda.	AIO - Instituto de Câncer de Brasília Ltda.	Total merged balances
Assets	117,683	30,736	20,831	169,250
Cash and cash equivalents	34	2,452	9,586	12,072
Accounts receivable	-	-	273	273
Recoverable taxes	340	-	-	340
Related parties receivable	6,113	2	22	6,137
Dividends receivable	1,924	-	-	1,924
Other assets	-	8,438	3,132	11,570
Investments	109,272	-	-	109,272
Property, plant and equipment	-	7,825	4,119	11,944
Intangible assets	-	2,755	2,163	4,918
Right-of-use and leased assets	-	9,264	1,536	10,800
Liabilities	(16,942)	(9,829)	(1,695)	(28,466)
Tax liabilities	(331)	-	-	(331)
Dividends payable	(10,473)	-	-	(10,473)
Related parties payable	(6,137)	-	-	(6,137)
Lease	-	(9,780)	(1,695)	(11,475)
Other liabilities	(1)	(49)	-	(50)
Shareholders' equity	(100,741)	(20,907)	(19,136)	(140,784)
Profit reserve	(66,369)	6,123	(4,355)	(64,601)
Capital	(34,372)	(27,030)	(14,781)	(76,183)

The operations did not generate impacts on the Company's Consolidated Financial Information.

2. DESCRIPTION OF SIGNIFICANT ACCOUNTING POLICIES - MATERIAL AND CLARIFYING

2.1 Statement of conformity

The Company's individual and consolidated interim financial information has been prepared in accordance with technical pronouncement CPC 21 (R1) - "Interim Financial Reporting" and IAS 34 - Interim Financial Reporting issued by IASB – International Accounting Standards Board and presented in line with the standards issued by the Brazilian Securities and Exchange Commission ("CVM"), applicable to the preparation of Interim Financial Information (ITR).

All relevant transactions of other relevant interim financial information, and only this information, are being highlighted and correspond to those used in the Company's management.

2.2 Basis of preparation

This interim financial information was prepared following preparation basis of preparation and accounting policies consistent with those adopted in financial statements as of December 31, 2024 and should be read together.

2.3 Investments in subsidiaries and consolidation

The consolidated interim financial information includes the operations of the Company and its associated companies and subsidiaries. Only the changes in the Group's equity interests in the investees, occurred in the three-month period ended March 31, 2025, are described below:

Investee (%)	03/31/2025			12/31/2024		
	Direct	Indirect	Total	Direct	Indirect	Total
Centro Paulista de Oncologia S.A. (i)	43.58	56.38	99.99	39.40	60.56	99.96
Céu de Brasília Participações S.A. (ii)	-	-	-	100.00	-	100.00
Núcleo de Hematologia e Transplante de Medula Óssea de MG Ltda. (i)	88.24	11.76	100.00	87.52	12.48	100.00
Hematológica - Clínica de Hematologia S.A. (i)	52.17	47.83	100.00	43.24	56.76	100.00
Idengene Medicina Diagnóstica S.A. (i)	-	100.00	100.00	100.00	-	100.00
CPO - Centro Paraibano de Oncologia S.A. (ii)	-	99.99	99.99	14.00	86.00	100.00
Núcleo de Oncologia da Bahia S.A. (iii)	51.35	32.00	83.35	48.17	31.99	80.16
Radioterapia Botafogo S.A. (i)	71.05	28.95	100.00	70.00	30.00	100.00

(i) They relate to changes in relative interest due to capital changes between Group's companies.

(ii) Corporate restructuring, as mentioned in Note 1.

(iii) Acquisition of percentage, as mentioned in Note 10.

2.4 Comparability

The statement of income for the year ended March 31, 2025 includes the full results of all the Company's subsidiaries.

The parent company's statement of income as of March 31, 2024 does not include the operations related to the assets being spun-off in February 2025 of the companies AIO – Instituto de Câncer de Brasília Ltda. and CETTRO – Centro de Tratamento Oncológico Ltda.

The reading of the financial information must consider these aspects.

3. NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS OF STANDARDS

In the three-month period ended March 31, 2025, the new applicable standards were evaluated and did not have any effects on the disclosed Interim Financial Information. Furthermore, the Company did not adopt the standards issued and not yet effective in advance.

4. CASH AND CASH EQUIVALENTS

Interest earning bank deposits are mainly represented by Bank Deposit Certificates (CDBs) yielding interest corresponding to rates of up to 98.44% as of March 31, 2025 (97.93% as of December 31, 2024) of the Interbank Deposit Certificate (CDI) rate, highly liquid.

	Parent Company		Consolidated	
	03/31/2025	12/31/2024	03/31/2025	12/31/2024
Cash and banks	15,170	35,414	118,626	78,119
Interest earning bank deposits	156,342	193,398	431,893	472,625
Total	171,512	228,812	550,519	550,744

5. SECURITIES AND OTHER FINANCIAL ASSETS

	Parent Company		Consolidated	
	03/31/2025	12/31/2024	03/31/2025	12/31/2024
Fixed income investments	792,716	1,040,032	1,107,895	1,467,551
Total	792,716	1,040,032	1,107,895	1,467,551
Current (i)	790,605	937,548	1,088,317	1,337,630
Non-current (ii)	2,111	102,484	19,578	129,921

(i) The short-term interest earning bank deposits refer to investments in fixed income securities.

It considers the amount of R\$ 88,405, related to investments made in April 2023 by the subsidiary Multihemo, maturing in April 2025. Long-term interest earning bank deposits are substantially derived from fixed income fund units and financial bills.

The yield of investments in securities has a remuneration between 104% and 120% of the CDI as of March 31, 2025 (104% and 120% of CDI as of December 31, 2024).

6. TRADE ACCOUNTS RECEIVABLE

	Parent Company		Consolidated	
	03/31/2025	12/31/2024	03/31/2025	12/31/2024
Clients	40,254	69,939	802,747	840,789
Unbilled revenues	200,802	194,917	1,352,545	1,330,494
Renegotiations	214,862	192,062	636,528	500,639
Total trade accounts receivable and unbilled revenues	455,918	456,918	2,791,820	2,671,922
Provision for expected credit loss (ECL) and disallowance	(20,366)	(15,378)	(298,616)	(237,328)
Total	435,552	441,540	2,493,204	2,434,594
Current	265,399	288,180	1,987,845	2,049,014
Non-current	170,153	153,360	505,359	385,580

Trade accounts receivable are denominated in Brazilian reais and mainly refer to services provided to healthcare plans, whose average collection period recorded in the three-month period ended March 31, 2025 was 135 days (118 days for the first quarter of 2024).

The breakdown of accounts receivable per maturity date is stated as follows:

	Parent Company		Consolidated	
	03/31/2025	12/31/2024	03/31/2025	12/31/2024
Falling due	322,218	403,553	1,711,288	1,772,371
Overdue (days):				
≤30	57,719	2,707	200,927	115,306
≤60	34,008	7,440	118,599	115,915
≤90	13,062	8,590	147,106	134,254
91–180	6,930	4,732	193,230	141,567
>180	21,981	29,896	420,670	392,509
Total	455,918	456,918	2,791,820	2,671,922

Changes in the provision for expected credit loss and disallowance are as follows:

	Parent Company	Consolidated
Balance at December 31, 2023	(17,992)	(174,836)
Formation	(7,959)	(77,861)
Reversal	4,155	28,899
Balance at March 31, 2024	(21,796)	(223,798)
Balance at December 31, 2024	(15,378)	(237,328)
Reversal	4,947	44,557
Formation	(9,814)	(105,845)
Corporate restructurings	(121)	-
Balance at March 31, 2025	(20,366)	(298,616)

In March 2025, a private debt confession instrument was executed between the Oncoclínicas Group and Unimed of the State of Rio de Janeiro – State Federation of Medical Cooperatives - “Unimed Ferj.” Unimed Ferj assumes the amount payable of R\$ 162,184, arising from receivables of medical services

performed by Oncoclínicas Group for beneficiaries of health plans operated by Unimed Rio. The amount will be paid in 110 monthly installments, monthly adjusted by the CDI change plus 1.5% p.a.

The maximum exposure to credit risk on the balance sheet date is the book value of each of the types of accounts receivable mentioned above. The Company has overdue balances for which a provision for loss has not been formed, considering the existence of ongoing negotiations, as well as agreements entered into with paying sources, which include certain mechanisms that may be judicially required for the settlement of said debts.

The Company believes that the provisioned amount and the disclosed expected losses are sufficient for the risks inherent to the receivables.

7. INVENTORIES

The amounts recorded in inventories refer mainly to medicines and hospital supplies. There is no provision for inventory losses and guarantees, considering an average turnover period of approximately 16 days for the quarter ended March 31, 2025 (23 days for the quarter ended March 31, 2024). Additionally, there are no guarantees provided and/or restrictions on the full use of inventories.

	Parent Company		Consolidated	
	03/31/2025	12/31/2024	03/31/2025	12/31/2024
Medicines	28,757	43,375	146,924	187,869
Material and Personal Protective Equipment (PPE)	10,800	10,267	43,204	37,366
Total	39,557	53,642	190,128	225,235

8. RECOVERABLE TAXES

Recoverable taxes are broken down as follows:

	Parent Company		Consolidated	
	03/31/2025	12/31/2024	03/31/2025	12/31/2024
IRPJ/CSLL	29,735	45,909	112,023	181,403
Withholding IRRF/CSLL	5,282	13,644	17,347	34,323
PIS/COFINS	3,999	21,052	43,608	76,549
Payroll taxes	17,239	20,605	17,276	20,642
Other taxes	222	276	557	1,182
Total	56,477	101,486	190,811	314,099

9. OTHER ASSETS

Other assets are shown as follows:

	Parent Company		Consolidated	
	03/31/2025	12/31/2024	03/31/2025	12/31/2024
Advances to suppliers	17,246	15,144	72,884	64,237
Disposal of equity interests (a)	10,308	10,051	11,216	10,975
Indemnity assets (b)	20,427	9,426	46,885	50,084
Machinery lease	4,791	4,361	-	-
Sundry advances (c)	185,398	187,109	267,319	266,267
Prepaid expenses	14,514	16,233	21,903	23,533
Other	6,867	6,795	34,917	31,580
Total	259,551	249,119	455,124	446,676
Current	61,371	51,147	178,561	151,871
Non-current	198,180	197,972	276,563	294,804

a) Refers to transactions involving the sale of equity interest formalized between the Company, its subsidiaries

and third parties. Balances are restated according to CDI and IPCA and mature up to 2030.

- b) Includes amounts resulting from indemnifiable events by former controlling shareholders of entities acquired by the Group, with R\$ 31,216 related to contingencies, according to Note 21, and R\$ 15,669 related to tax liabilities linked to self-regularization.
- c) It includes R\$ 65,149, anticipated during the 1st quarter of 2024 for the start of construction under the Built To Suit contract signed in January 2023 between Goiânia Medical Center Ltda (Lessor) and Oncoclínicas do Brasil Serviços Médicos S.A. (Lessee).

Includes an amount of R\$ 118,079, prepaid during the first semester of 2024 for the start of construction under the Built To Suit contract signed in October 2023 between Cedro Participações S.A. (Lessor) and Oncoclínicas do Brasil Serviços S.A. (Lessee).

Includes an amount of R\$ 67,029, prepaid for the start of construction under the Built To Suit contract signed in December 2023 between Castelo Byblos Participações S.A. (Lessor) and Oncoclínicas do Brasil Serviços Médicos S.A. (Lessee).

The project are in progress, and the recognition criteria established by IFRS 16 (CPC 06) have not yet been met.

10. INVESTMENTS IN SUBSIDIARIES AND ASSOCIATED COMPANIES

a) Breakdown

	Parent Company		Consolidated	
	03/31/2025	12/31/2024	03/31/2025	12/31/2024
Investments	2,659,399	2,627,171	51,578	42,960
Goodwill (i)	1,137,894	1,122,929	-	-
Call options (ii)	24,390	31,815	-	-
Total	3,821,683	3,781,915	51,578	42,960

(i) It refers to goodwill arising from business combinations carried out by the parent company, as well as by subsidiaries that have been merged. The change in the amount of R\$ 14,963 refers to the addition of the goodwill from the investee Centro Paraibano de Oncologia S.A, derived from the downstream merger transaction between this investee and Centro Mineiro de Infusões S.A.

(ii) Refers to stock options granted by minority shareholders to Núcleo de Oncologia da Bahia S.A., as described in Note 20. The reduction in the amount of R\$ 7,425 refers to the execution of the call option for 3.17% equity interest of the minority interest by the Company in January 2025.

b) Changes in the balances of parent company's investments are as follows:

Companies	12/31/2024	Capital increase and decrease (i)	Equity in net income of subsidiaries	Changes in interest (iii)	Exchange-rate change	Corporate restructuring (ii)	03/31/2025
Chemotherapy	920,806	64,274	(9,829)	534	2,746	191,351	1,169,882
Radiotherapy	30,787	370	1,268	(4)	-	-	32,421
Precision medicine	97,239	12,200	5,758	-	(4,130)	(107,640)	3,427
Vehicle entities	1,402,945	32,595	(18,501)	5,448	-	(130,187)	1,292,300
Other	128,492	20,089	(12,634)	(2,319)	(2,298)	-	131,330
Total	2,580,269	129,528	(33,938)	3,659	(3,682)	(46,476)	2,629,360
Investments	2,627,171						2,659,399
Provision for investment loss	(46,902)						(30,039)

Companies	12/31/2023	Capital increase	Equity in net income of subsidiaries	Changes in interest	Exchange-rate change	Corporate restructuring	Other transactions with shareholders	03/31/2024
Chemotherapy	591,650	69,583	23,532	(14,927)	-	192	(17)	670,013
Radiotherapy	30,170	-	844	-	-	-	-	31,014
Precision medicine	200,248	20,562	(14,195)	7	(30)	47,545	-	254,137
Vehicle entities	1,429,518	40,493	(10,950)	(11)	(1)	(47,737)	(260)	1,411,052
Other	87,979	3,388	(3,683)	-	-	-	-	87,684
Total	2,339,565	134,026	(4,452)	(14,931)	(31)		(277)	2,453,900
Investments	2,351,966							2,483,590
Provision for investment loss	(12,401)							(29,690)

c) Changes in the balances of investments (consolidated) are as follows:

Companies	12/31/2024	Equity in net income of subsidiaries	Exchange-rate change	Changes in interest (iii)	03/31/2025
Medica Scientia Innovation Research	11,939	14,538	(1,303)	-	19,489
JV Saudi Arabia	36,706	-	(2,298)	2,319	32,089
Total	42,960	14,538	(3,601)	2,319	51,578

Investments	42,960	51,578
--------------------	---------------	---------------

Companies	12/31/2023	Equity in net income of subsidiaries	Exchange-rate change	03/31/2024
Medica Scientia Innovation Research	11,939	(1)	(17)	11,921
Total	11,939	(1)	(17)	11,921

Investments	14,727	14,727
Provision for investment loss	(2,788)	(2,806)

(i) Capital increase and capital reduction

During the three months ended March 31, 2025, capital increases of R\$ 140,768 were made in the Company's direct subsidiaries through the balance of advance for future capital increase.

Furthermore, there was a capital decrease in the investee Oncohematologia Participações Ltda., in the amount of R\$ 11,240, through credit granting to Oncoclínicas do Brasil S.A.

(ii) Corporate Restructuring

As mentioned in Note 01, the Company carried out the merger of the partially spun-off net assets of the companies AIO – Instituto de Câncer de Brasília Ltda. and CETTRO – Centro de Tratamento Oncológico Ltda. The impacts of the operations by company on the investment of the Parent Company are as follows:

AIO – Instituto de Câncer de Brasília Ltda.	(20,907)
CETTRO – Centro de Tratamento Oncológico Ltda.	(19,136)
	(40,043)

As mentioned in Note 01, in February 2025, the total merger of the company Céu de Brasília Participações S.A. was carried out.

The impact on the parent company's investment is presented below:

	Investment effect
Effect of the increase in direct investment in AIO - Instituto de Câncer de Brasília Ltda.	56,935
Effect of the increase in direct investment in CETTRO – Centro de Tratamento Oncológico Ltda.	52,337
Effect of the write-off of the direct equity interest in Céu de Brasília Participações S.A.	(100,741)
	8,530

Furthermore, a downstream merger of Centro Mineiro de Infusões S.A. into Centro Paraibano de Oncologia S.A. was carried out, as mentioned in Note 01. The transaction took place in January 2025 and had the effect of a decrease in the parent company's investment of R\$ 14,963 due to the capital decrease at Centro Mineiro de Infusões S.A. resulting from this transaction.

(iii) Change in interest and other transactions with shareholders

In January 2025, the call option granted by the minority shareholders was exercised, representing 3.17% of the capital of the company Núcleo de Oncologia da Bahia S.A. The transaction generated an increase in the investment in the Parent Company of R\$ 7,425 in exchange for the call options and an effect of a gain of R\$ 2,527 in the investment balances in the Parent Company.

In January 2025, Oncoclínicas made an advance for future capital increase to the investee NOB, with R\$ 1.00 allocated to the Capital account and R\$ 20,038 allocated to the Capital Reserve account (Capital Reserve Premium on Subscription). The transaction resulted in a loss of R\$ 3,973 in the Parent Company's investment.

Furthermore, in January 2025, there was a capital contribution from the Company to the foreign investee Medica Scientia Innovation Research. The transaction generated a loss effect on the investment in the Parent Company of R\$ 2,320.

Company	Equity interest of subsidiaries, direct investees						
	March 31, 2025						
Company	Interest	Total Assets	Total liabilities	Shareholders' equity	Income (loss) for the year	Investment amount	MEP income (loss) - from direct investees
Oncoclínica Centro de Tratamento Oncológico S.A.	100%	215,713	20,555	195,158	(7,001)	195,158	(7,001)
Oncoclínicas Salvador S.A.	100%	16,439	1,916	14,523	720	14,523	720
Radioterapia Botafogo S.A.	71%	31,117	18,962	12,155	1,622	8,636	1,157
Centro Mineiro de Infusões S.A.	100%	712,720	130,603	582,117	7,304	582,117	(7,304)
Núcleo de Oncologia da Bahia Ltda	51%	935,544	656,706	278,838	(34,679)	143,180	(17,807)
Oncocentro Imagem Serviços Médicos Ltda.	100%	170,723	31,360	139,363	5,111	139,363	5,111
Oncopar Sul Empreendimentos e Participações Ltda.	100%	67,966	(238)	68,204	948	68,204	948
Oncologia Participações Ltda.	100%	29,804	286	29,518	(156)	29,515	(156)
Oncohematologia Participações Ltda.	100%	27,431	941	26,490	940	26,389	937
Oncobio Serviços de Saúde S.A.	100%	156,182	54,549	101,633	(9,518)	101,633	(9,518)
Instituto de Oncologia de Ribeirão Preto S.A.	5%	21,571	12,871	8,700	1,014	391	46
Radioterapia Oncoclínicas São Paulo Ltda.	99%	18,770	12,674	6,096	413	6,029	408
Centro de Excelência de Radioterapia Oncoclínicas Rio de Janeiro Ltda	50%	9,547	8,776	771	(2,107)	385	(1,054)
Radioterapia Oncoclínicas Recife S.A.	7%	49,973	19,627	30,346	532	2,124	37
CGS Faria Lima	100%	11,585	5,985	5,600	411	5,594	411
Oncoclínicas Participações ES RJ Ltda.	100%	180,501	24	180,477	(9,617)	180,462	(9,616)
Navarra RJ (Leste Fluminense S.A.)	51%	349,521	258,750	90,771	4,473	46,293	2,281
Andromeda Participações S.A.	100%	288,317	38,899	249,418	(12,442)	249,418	(12,442)
Cruz Participações Ltda (Talassa Participações S.A.)	50%	85,953	35,546	50,407	(212)	25,208	(106)
CTC Oncologia S.A.	50%	11,874	6,418	5,456	25	2,728	13
Locus Anat. Patol. E Citologia Ltda.	9%	10,960	10,059	901	(1,707)	84	(158)
Talia Participações Ltda.	100%	4,190	2,140	2,050	197	2,048	197
CTR - Centro de Tratamento Radioterápico Ltda.	88%	9,700	1,955	7,745	194	6,781	170
Centro Paulista de Oncologia S.A.	44%	1,466,982	723,482	743,500	48,953	324,022	20,149
COTE – Centro Oncológico e Tratamento	100%	7,371	4,160	3,211	(1,460)	3,211	(1,460)
Unity Participações S.A.	100%	539,805	225,851	313,954	2,541	313,013	2,412
Cetro – Centro de Tratamento Oncológico S.A.	100%	116,576	85,404	31,172	(691)	31,172	(677)
Instituto De Cancer De Brasília Ltda.	100%	144,282	111,435	32,847	(5,003)	32,847	(5,001)
Onco Vida – Instituto Especializado de Oncologia Ltda	100%	110,391	91,081	19,310	3,608	19,234	3,594
Aliança Instituto de Oncologia	100%	108,861	95,402	13,459	(9,039)	13,398	(8,998)
Centro Brasileiro de Radioterapia Oncologia e Mastologia Cebrom Ltda.	32%	239,965	160,482	79,483	13,081	25,155	4,140
Hematológica – Clínica de Hematologia S.A.	52%	69,122	13,547	55,575	4,189	28,995	2,322

Céu de Brasília Participações S.A.	100%	-	-	-	-	-	3,400
JV Saudi Arabia	51%	62,920	-	62,920	-	32,089	-
Idengene Medicina Diagnóstica Ltda.	-	-	-	-	-	-	5,758
Total investment		6,282,376	2,840,208	3,442,168	(11,964)	2,659,399	(27,087)

Company	Interest	Total Assets	Total liabilities	Shareholders' equity	Income (loss) for the year	Investment amount	MEP income (loss) - from direct investees
Radioterapia Oncoclínicas Salvador Ltda.	100%	-	6	(6)	-	(5)	(1)
Radioterapia Oncoclínicas Ribeirão Preto Ltda.	99%	2	10	(8)	-	(8)	-
CTR Centro de Tratamento de Anápolis	87%	24,324	29,727	(5,403)	(958)	(4,684)	(831)
Pontus Participações S.A.	100%	13,765	35,748	(21,983)	518	(21,983)	518
Núcleo de Hematologia e Transplante de Medula Ossea Ltda.	88%	11,155	13,806	(2,651)	(5,993)	(2,339)	(5,289)
OC Franquias Ltda.	100%	307	1,327	(1,020)	(1,248)	(1,020)	(1,248)
Total unsecured liability		49,553	80,624	(31,071)	(7,681)	(30,039)	(6,851)
Total direct investments		6,331,929	2,920,832	3,411,097	(19,645)	2,629,360	(33,938)

Equity interest of subsidiaries, direct investees

March 31, 2024

Company	Interest	Total Assets	Total liabilities	Shareholders' equity	Income (loss) for the year	Investment amount	MEP income (loss) - from direct investees
Oncoclínicas Salvador S.A.	100.00%	17,097	3,764	13,333	21	13,334	21
Radioterapia Botafogo S.A.	70.00%	28,260	18,893	9,367	973	6,557	681
Centro Mineiro de Infusões S.A.	100.00%	914,799	232,339	682,460	(11,538)	682,460	(11,538)
Núcleo de Oncologia da Bahia Ltda	48.17%	963,434	595,443	367,991	(7,341)	177,278	(3,536)
Oncocentro Imagem Serviços Médicos Ltda.	99.99%	191,632	45,569	146,063	5,686	146,049	5,686
Oncopar Sul Empreendimentos e Participações Ltda.	100%	73,330	4,510	68,820	1,166	68,820	1,166
Oncologia Participações Ltda.	99.99%	89,861	323	89,538	850	89,530	850
CPO – Centro Paraibano de Oncologia S.A.	14.00%	42,141	24,777	17,364	512	2,431	72
Oncohematologia Participações Ltda.	99.62%	34,837	814	34,023	395	33,893	393
Oncobio Serviços de Saúde S.A.	100.00%	133,471	44,351	89,120	(1,778)	89,121	(1,778)
Instituto de Oncologia de Ribeirão Preto S.A.	4.50%	17,092	10,671	6,421	1,350	289	61
Radioterapia Oncoclínicas São Paulo Ltda.	98.90%	17,485	12,862	4,623	580	4,573	574
Centro de Excelência de Radioterapia Oncoclínicas Rio de Janeiro Ltda	50.00%	11,420	3,866	7,554	(872)	3,777	(436)
Radioterapia Oncoclínicas Recife S.A.	7.00%	52,931	23,700	29,231	70	2,046	5
CGS Faria Lima	99.90%	4,710	1,249	3,461	(37)	3,457	(37)
Idengene Medicina Diagnóstica S.A.	95.44%	336,131	73,343	262,788	(14,970)	250,708	(14,195)
Oncoclínicas Participações ES RJ Ltda.	99.99%	108,033	36	107,997	9,486	107,989	9,485

Equity interest of subsidiaries, direct investees							
March 31, 2024							
Company	Interest	Total Assets	Total liabilities	Shareholders' equity	Income (loss) for the year	Investment amount	MEP income (loss) - from direct investees
Navarra RJ (Leste Fluminense S.A.)	51.00%	223,421	106,430	116,991	7,272	59,665	3,709
Andromeda Participações S.A.	100.00%	188,002	51,419	136,583	(11,314)	136,583	(11,314)
Cruz Participações Ltda (Talassa Participações S.A.)	50.01%	84,285	34,617	49,668	876	24,839	438
CTC Oncologia S.A.	50.00%	246,105	6,380	239,725	(2)	119,863	(1)
Hematológica – Clínica de Hematologia S.A.	16.03%	179,355	166,615	12,740	5,599	2,043	910
Locus Anat. Patol. E Citologia Ltda.	9.28%	13,262	4,512	8,750	(1,135)	812	(104)
Talia Participações Ltda.	99.90%	2,388	1,367	1,021	43	1,020	43
Centro Brasileiro de Radioterapia Oncologia e Mastologia Cebrom Ltda.	31.65%	215,314	103,518	111,796	2,570	35,380	813
Centro Paulista de Oncologia S.A.	53.55%	1,143,597	844,110	299,487	4,051	160,376	2,166
COTE – Centro Oncológico e Tratamento	100.00%	4,214	1,777	2,437	(1,057)	2,437	(1,057)
ONCO VIDA – Instituto Especializado de Oncologia Ltda	99.60%	91,306	85,491	5,815	1,417	5,764	1,752
Aliança Instituto de Oncologia	99.54%	90,700	71,214	19,486	1,021	19,364	1,356
Unity Participações S.A.	100.00%	588,483	355,664	232,819	14,158	232,734	14,292
JHSL Consultoria	55.46%	4,455	3,736	719	(11)	398	(6)
Total investment		6,111,551	2,933,360	3,178,191	8,041	2,483,590	471
Company	Interest	Total Assets	Total liabilities	Shareholders' equity	Income (loss) for the year	Investment amount	MEP income (loss)-from direct investees
Radioterapia Oncológicas Salvador Ltda.	68.06%	-	10	(10)	(2)	(7)	(1)
Oncoclínicas Centro de Tratamento Oncológico	100%	9,926	16,191	(6,265)	1,935	(6,265)	1,935
Radioterapia Oncoclínicas Ribeirão Preto Ltda.	99.09%	6	10	(4)	-	(4)	-
Pontus Participações Ltda.	100%	30,439	36,303	(5,864)	(2,794)	(5,864)	(2,794)
CTR Centro de Tratamento de Anápolis	86.69%	23,313	25,856	(2,543)	(1,250)	(2,205)	(1,084)
OC Serviços Ltda.	100%	4,236	7,592	(3,356)	(3,356)	(3,356)	(3,356)
CTR - Centro de Tratamento Radioterápico Ltda.	87.56%	9,030	22,721	(13,691)	430	(11,988)	377
Total unsecured liability		76,950	108,683	(31,733)	(5,037)	(29,690)	(4,923)
Total direct investments		6,188,501	3,042,043	3,146,458	3,004	2,453,900	(4,552)

Consolidated financial position							
March 31, 2025							
Company	Interest	Total Assets	Total liabilities	Shareholders' equity	Income (loss) for the year	Investment amount	MEP Income (loss)
Medica Scientia Innovation Research	49.00%	132,994	94,780	38,214	29,669	19,489	14,538
JV Saudi Arabia	51.00%	62,920	-	62,920	-	32,089	-
Total consolidated investments		195,913	94,780	101,133	29,669	51,578	14,538

Consolidated financial position							
March 31, 2024							
Company	Interest	Total Assets	Total liabilities	Shareholders' equity	Income (loss) for the year	Investment amount	MEP Income (loss)
Medica Scientia Innovation Research	49.00%	69,683	75,532	(5,849)	1	(2,806)	(1)
Total consolidated unsecured liability		69,683	75,532	(5,849)	1	(2,806)	(1)

11.PROPERTY, PLANT AND EQUIPMENT

Parent Company					
		03/31/2025		12/31/2024	
Description	Annual average depreciation rates	Cost	Accumulated depreciation	Balance	Balance
Machinery and equipment	10%	77,872	(37,435)	40,437	36,149
Facilities	10%	971	(809)	162	156
Furniture and fixtures	10%	13,292	(8,056)	5,236	4,800
Computers and peripherals	20%	27,549	(15,535)	12,014	11,089
Leasehold improvements	10%	113,339	(45,570)	67,769	67,610
Land	-	986	-	986	986
Construction in progress	-	8,421	-	8,421	5,495
Total		242,430	(107,405)	135,025	126,285

Consolidated					
		03/31/2025		12/31/2024	
Description	Annual average depreciation rates	Cost	Accumulated depreciation	Balance	Balance
Machinery and equipment	10%	548,181	(299,741)	248,440	258,363
Facilities	10%	11,796	(8,255)	3,541	3,787
Furniture and fixtures	10%	76,876	(44,043)	32,833	32,238
Computers and peripherals	20%	80,629	(50,891)	29,738	31,606
Leasehold improvements	10%	575,648	(224,032)	351,616	362,824
Vehicles	20%	659	(659)	-	-
Land	-	5,396	-	5,396	5,396
Construction in progress	-	139,678	-	139,678	128,311
Total		1,438,863	(627,621)	811,242	822,525

On March 31, 2025, the balance of property, plant and equipment pledged as collateral was R\$ 5,931 (R\$ 7,687 on December 31, 2024). Management has not identified significant differences in the economic useful lives of the assets part of its property, plant and equipment and of its subsidiaries.

Leasehold improvements are amortized over the term of the lease agreement and the expected renewal or disposal are considered, when Management intends to exercise this right, and pursuant to the terms of the agreements. Land and constructions in progress are not depreciated or amortized.

	Parent Company							
	Machinery and equipment	Facilities	Furniture and fixtures	Computers and peripherals	Leasehold improvements	Construction in progress	Land	Total
Balance at December 31, 2023	38,150	193	2,537	8,014	15,628	26,282	986	91,790
Acquisitions	58	-	37	1,331	109	1,704	-	3,239
Depreciation	(1,631)	(15)	(147)	(630)	(1,161)	-	-	(3,584)
Transfers	611	-	-	-	16,999	(16,637)	-	973
Balance at March 31, 2024	37,188	178	2,427	8,715	31,575	11,349	986	92,418
Balance at December 31, 2024	36,149	156	4,800	11,089	67,610	5,495	986	126,285
Acquisitions	12	-	5	507	132	1,907	-	2,563
Depreciation	(1,521)	(15)	(227)	(902)	(3,102)	-	-	(5,767)
Write-offs	-	-	-	-	-	-	-	-
Corporate restructuring	5,797	21	658	1,320	3,129	1,019	-	11,944
Balance at March 31, 2025	40,437	162	5,236	12,014	67,769	8,421	986	135,025

	Consolidated							
	Machinery and equipment	Facilities	Furniture and fixtures	Computers and peripherals	Leasehold improvements	Land	Construction in progress	Total
Balance at December 31, 2023	317,007	4,780	30,244	28,148	320,244	5,396	124,271	830,090
New companies	-	-	-	-	-	-	-	-
Acquisitions	5,504	-	2,199	3,545	3,877	-	43,839	58,964
Depreciation	(11,877)	(252)	(1,125)	(2,151)	(8,817)	-	-	(24,222)
Write-offs	13	-	18	22	(4)	-	-	49
Transfers	4,196	-	16	-	39,713	-	(28,691)	(15,234)
Balance at March 31, 2024	314,843	4,528	31,352	29,564	355,013	5,396	139,419	880,115
Balance at December 31, 2024	258,363	3,787	32,238	31,606	362,824	5,396	128,311	822,525
Acquisitions	1,256	-	2,340	2,894	460	-	11,214	18,164
Depreciation	(11,147)	(246)	(1,387)	(2,715)	(11,941)	-	-	(27,436)
Write-offs	(42)	-	(4)	(1,986)	21	-	-	(2,011)
Transfers	10	-	(354)	(61)	252	-	153	-
Balance at March 31, 2025	248,440	3,541	32,833	29,738	351,616	5,396	139,678	811,242

The Company evaluated the impairment indicators and for the three-month period ended March 31, 2025, the indication to recognize a provision for asset impairment was not identified.

12. INTANGIBLE ASSETS

The intangible assets of the Company and its subsidiaries are comprised of systems and applications, exclusivity right, software development, trademarks and patents, partnership agreements, intellectual property and goodwill deriving from expected future earnings paid on the acquisition of investments, pursuant to rental reports prepared by external specialists. Goodwill arising from the acquisition of investments in subsidiaries is reclassified from the investment group in the parent company's Financial Information to intangible assets in the consolidated Financial Information.

The amounts recorded in intangible assets are as follows:

Description	Annual rates of amortization	Parent Company			
				03/31/2025	12/31/2024
		Cost	Accumulated amortization	Balance	Balance
Systems and applications	20%	236,235	(88,685)	147,550	151,723
Exclusivity right	25%	43,281	(34,990)	8,291	7,159
Software development	-	78,435	-	78,435	68,368
Goodwill	-	9,585	-	9,585	9,585
Intellectual property	20%	87,946	(37,382)	50,564	53,193
Partnership agreement	8.33%	112,322	(13,603)	98,719	100,286
Total		567,804	(174,660)	393,144	390,314

Description	Annual rates of amortization	Consolidated			
				03/31/2025	12/31/2024
		Cost	Accumulated amortization	Balance	Balance
Systems and applications	20%	281,814	(121,404)	160,410	167,589
Software development	20%	86,331	-	86,331	76,773
Exclusivity right	-	163,397	(118,467)	44,930	49,223
Goodwill	-	2,404,765	-	2,404,765	2,404,765
Partnership agreements	8.33%	1,099,502	(112,476)	987,026	997,471
Trademarks and patents	-	191	-	191	191
Intellectual property	20%	90,690	(38,950)	51,740	54,505
Total		4,126,690	(391,297)	3,735,393	3,750,517

There are no rights pledged in guarantee as of March 31, 2025 and December 31, 2024. The Company's management did not identify significant differences in the economic useful life of the assets that comprise its intangible assets and those of its subsidiaries.

	Parent Company							
	Systems and applications	Software under development	Goodwill	Exclusivity right	Trademarks and patents	Intellectual Property	Partnership agreement	Total
Balance at December 31, 2023	79,791	34,748	9,585	12,031	358	71,755	262,514	470,782
Acquisition	1,336	18,694	-	34	-	-	-	20,064
Amortization	(9,618)	-	-	(1,452)	-	(1,921)	(3,241)	(16,232)
Transfers	4,910	(5,883)	-	-	-	-	-	(973)
Balance at March 31, 2024	76,419	47,559	9,585	10,613	358	69,834	259,273	473,641
Balance at December 31, 2024	151,723	68,368	9,585	7,159	-	53,193	100,286	390,314
Acquisitions	608	11,324	-	-	-	-	-	11,932
Amortization	(9,364)	-	-	(448)	-	(2,629)	(1,579)	(14,020)
Transfers	1,877	(1,877)	-	-	-	-	-	-
Corporate restructuring (ii)	2,706	620	-	1,580	-	-	12	4,918
Balance at March 31, 2025	147,550	78,435	9,585	8,291	-	50,564	98,719	393,144

							Consolidated	
	Systems and applications	Software under development	Goodwill	Exclusivity right	Trademarks and patents	Intellectual Property	Partnership agreement	Total
Balance at December 31, 2023	169,832	64,902	2,669,970	73,407	779	74,234	1,137,480	4,190,604
Acquisition	1,369	27,326	-	355	-	-	294,896	323,946
Amortization	(19,175)	-	-	(6,925)	-	(1,921)	(8,496)	(36,517)
Exchange-rate change	-	-	999	-	-	-	-	999
Transfers	9,522	(24,756)	-	-	-	-	-	(15,234)
Balance at March 31, 2024	161,548	67,472	2,670,969	66,837	779	72,313	1,423,880	4,463,798
Balance at December 31, 2024	167,589	76,773	2,404,765	49,223	191	54,505	997,471	3,750,517
Acquisitions	1,526	11,572	-	-	-	-	(276)	12,828
Amortization	(10,702)	-	-	(4,293)	-	(2,765)	(10,169)	(27,929)
Write-offs	(23)	-	-	-	-	-	-	(23)
Transfers	2,020	(2,020)	-	-	-	-	-	-
Balance at March 31, 2025	160,410	86,331	2,404,765	44,930	191	51,740	987,026	3,735,393

(i) Partnership agreements

Oncoclínicas establishes partnerships with medical institutions for oncological services, investing in exchange for a flow of patients. Amortization occurs during the term of each partnership contract.

(ii) Exclusivity right

The right of non-competition registered in the companies of the Oncoclínicas Group refers to clauses evidenced in the contracts for the provision of medical services, which provide for the exclusivity right of such service providers. The average term of the contracts is approximately 4 years.

13. RIGHT-OF-USE AND LEASE LIABILITIES

The Group leases properties for its operations, including buildings. The average lease term is ten years. The Group's obligations are guaranteed by the ownership of the leased assets.

13.1. Right-of-use assets

	Parent Company	Consolidated
Balance at December 31, 2023	14,693	404,992
Addition	118	2,752
Amortization	2,547	(6,910)
Balance at March 31, 2024	17,358	400,834
Balance at December 31, 2024	45,760	513,306
Write-off	(981)	(981)
Addition	39	84,556
Amortization	(3,496)	(18,744)
Corporate restructuring	10,800	-
Balance at March 31, 2025	52,122	578,137

13.2. Lease liabilities

Liabilities were measured at the present value of the remaining lease payments as discounted through the average incremental rate of 14.49% p.a. as of March 31, 2025 (15.59% p.a. for December 31, 2024). Due to the maturity and renewal of some lease contracts, they were remeasured at the new monthly amount, which additional amounts were classified as addition.

	Parent Company	Consolidated
Balance at December 31, 2023	22,356	412,345
Addition	118	2,752
Principal payments	(3,432)	(12,750)
Interest payment	(339)	(11,705)
Interest incurred	481	9,905
Balance at March 31, 2024	19,184	400,547
Balance at December 31, 2024	51,326	561,192
Write-off	(981)	(981)
Addition	39	84,556
Payment of principal	(3,646)	(12,148)
Interest payment	(1,716)	(16,400)
Interest incurred	1,640	15,643
Corporate restructuring	11,475	-

Balance at March 31, 2025	58,137	631,862
Current	15,130	52,686
Non-current	43,007	579,176

As of March 31, 2025, the breakdown of balance is as follows:

	Parent Company	Consolidated
2025	16,768	83,126
2026	15,375	107,114
2027	11,665	99,696
2028	9,264	84,605
2029	8,513	77,909
2030 onwards	21,857	1,106,441
Total	83,442	1,558,891
Embedded interest	(25,305)	(927,029)
Lease liabilities	58,137	631,862

Although the accounting methodology used by the Company is in line with the rule provided for in CPC 06(R2) /IFRS 16, it generates distortions in the information to be provided due to the mismatching between the cash flow and present value, considering the current reality of interest rates term in the Brazilian economic environment. Thus, the Company recalculated the depreciation and financial charges for the total effective period of the active agreements on March 31, 2025, based on a future cash flow that incorporates the inflationary expectation (nominal flow).

In compliance with Circular Letter/CVM/SNC/SEP/ 02/2019, the Company presents the comparative balances of lease liabilities and its respective financial expenses, right-of-use assets and its respective depreciation expenses, considering the effect of the projected future IPCA inflation in the lease contract flows, discounted at the nominal rate:

	Parent Company		Consolidated	
	IFRS 16	Inflation projected	IFRS 16	Inflation Projected
Right-of-use assets, net	52,122	57,855	578,137	740,015
Lease liabilities	58,137	64,532	631,861	902,130
Depreciation expenses	(3,496)	(4,487)	(18,744)	(24,936)
Financial expenses	(1,640)	(2,065)	(15,643)	(21,817)

The Company has no potential recoverable PIS/Pasep and COFINS embedded in the lease consideration.

14. SUPPLIERS

The amounts recorded as suppliers are mainly represented by balances payable to domestic suppliers of medicine. These medicines are used in oncological and medical procedures.

15. LOANS AND FINANCING

The amounts recorded as loans and financing are stated as follows:

Description	Index / Interest	Final maturities	Parent Company		Consolidated	
			03/31/2025	12/31/2024	03/31/2025	12/31/2024
Financing	CDI+2.5–5%p.a./ IPCA+1–2.8%p.a./ 4.75–11.67%p.a.	09/08/2031	-	-	35,790	38,434
CCB / Working capital (i)	CDI+0.75–9.38% p.a./ IPCA+1.21–2.011%p.a./ 8.60–27.87%p.a.	05/22/2028	167,392	263,471	600,763	721,597

CRI	CDI+1.16–1.91% p.a.	10/17/2033	1,471,678	1,426,534	1,471,678	1,426,534
Law 4131	CDI+1.73–2% p.a.	03/17/2026	169,697	224,939	169,697	224,939
FINEP	TJLP+0.5% p.a.	12/15/2031	55,794	57,595	55,794	57,595
			1,864,561	1,972,539	2,333,722	2,469,099
Current			357,484	425,903	435,864	522,860
Non-current			1,507,077	1,546,636	1,897,858	1,946,239

On March 25, 2025, Working Capital was raised for a total of R\$ 30,000 with remuneration interest corresponding to CDI + 1.90% p.a.

As of March 31, 2025, the Group follows the non-financial and financial covenants of the group's loans and financing, which is calculated annually.

The Company contracted certain swap instruments with the purpose of hedging fluctuations in price indices and hedging fluctuations in the USD. The details of these operations are presented in Note 28.

Derivative instruments – swap	Parent Company		Consolidated	
	03/31/2025	12/31/2024	03/31/2025	12/31/2024
Current and non-current assets	25,850	39,207	25,850	39,207
Current and non-current liabilities	(90,829)	(107,046)	(90,829)	(107,046)
Total loans, financing and debt securities, net of swaps	1,929,540	2,040,378	2,398,701	2,536,938

As of March 31, 2025, the weighted average cost of swaps is approximately 100% of the CDI rate + 1.54% p.a. The asset and liability position is disclosed in Note 28.

Changes in loans and financing balances in the three-month period ended March 31, 2025 and March 31, 2024, for the Group are presented below:

	Parent Company	Consolidated
Balance at December 31, 2023	1,803,934	2,398,807
Additions	164,994	175,375
Interest incurred	61,234	78,193
Loan cost	2,368	3,048
Payment of principal	(2,481)	(19,407)
Exchange-rate change	87	1,347
Payment of financial charges	(38,119)	(46,471)
Balance at March 31, 2024	1,992,287	2,590,892
Balance at December 31, 2024	1,972,539	2,469,099
Additions	30,000	38,111
Interest incurred	33,708	49,667
Loan cost	1,977	2,294
Payment of principal	(158,986)	(205,209)
Exchange-rate change	(7,506)	(7,502)
Adjustment to fair value	34,802	34,802
Payment of financial charges	(41,973)	(47,540)
Balance at March 31, 2025	1,864,561	2,333,722

Loan and financing settlement flow is as follows:

Settlement flow	Parent Company	Consolidated
2025	294,197	363,515
2026	114,336	450,140
2027	283,263	319,668
2028	222,985	240,740
2029	198,927	204,215
2030 onwards	750,853	755,444
Total	1,864,561	2,333,722

Oncoclínicas Group's exposure to interest rate risks and the sensitivity analysis for loans and financing are disclosed in Note 29.

Loan cost capitalized

For the twelve-month period ended March 31, 2025, the Company capitalized interest on loans attributed to qualifying assets totaling R\$ 156 (R\$ 1,402 as of March 31, 2024).

16. DEBENTURES

See below the breakdown of the debenture balances for the twelve-month period ended March 31, 2025 and for the year ended December 31, 2024 of the Group:

	Parent Company		Consolidated	
	03/31/2025	12/31/2024	03/31/2025	12/31/2024
Debentures	1,812,835	1,764,427	2,492,765	2,448,108
Total	1,812,835	1,764,427	2,492,765	2,448,108
Current	84,906	37,277	296,495	233,272
Non-current	1,727,929	1,727,150	2,196,270	2,214,836

The final maturity of the Company's debentures is on 11/26/2029, with interest rates ranging from CDI + 1.40% at CDI + 2.40% p.a.

Changes in Group's debenture balances in the three-month periods ended March 31, 2025 and March 31, 2024 are as follows:

	Parent Company	Consolidated
Balance at December 31, 2023	749,610	1,744,323
Amortization of debenture costs	558	1,192
Interest incurred	23,058	55,305
Payment of financial charges	-	(17,898)
Balance at March 31, 2024	773,226	1,782,922
Balance at December 31, 2024	1,764,427	2,448,108
Amortization of debenture cost	778	1,492
Interest incurred	59,686	83,536
Payment of principal	-	(20,058)
Payments of financial charges	(12,056)	(20,313)
Balance at March 31, 2025	1,812,835	2,492,765

The settlement flow can be demonstrated as follows:

Settlement flow	Parent Company	Consolidated
2025	84,906	273,760
2026	62,966	253,021
2027	687,516	877,572
2028	122,446	233,411
2029	855,001	855,001
Total	1,812,835	2,492,765

As of March 31, 2025, the Group is in compliance with the non-financial and financial covenants of its debenture agreements, which financial institutions are disclosed annually.

17. SOCIAL CHARGES

The amounts recorded as social charges are stated as follows:

	Parent Company		Consolidated	
	03/31/2025	12/31/2024	03/31/2025	12/31/2024
Salaries, social charges, and other remuneration (a)	67,215	67,001	157,698	155,182
Share-based payment program (b)	10,227	12,951	10,227	12,951
Total	77,442	79,952	167,925	168,133
Current	67,215	67,001	157,698	155,182
Non-current	10,227	12,951	10,227	12,951

(a) Other remunerations

The Oncoclínicas Group has a profit sharing program for employees according to the profit calculated each year. The annual amount payable is defined based on results and performance indicators.

(b) Share-based payment

Refers to taxes on the balance of the executive and employee compensation program, in the form of a share-based payment program.

18. TAX LIABILITIES

The amounts recorded as taxes payables are stated as follows:

Description	Parent Company		Consolidated	
	03/31/2025	12/31/2024	03/31/2025	12/31/2024
Withholding income tax (IRRF)	490	4,888	1,361	8,478
ISSQN	1,197	12,906	5,101	50,350
PIS and COFINS	2,516	3,163	18,437	43,964
Federal withholdings	742	807	2,477	5,761
Taxes in installments (i)	18,716	20,242	100,447	112,013
Tax on financial operations (IOF)	533	3,406	851	3,959
Other	409	522	4,010	5,855
Total	24,603	45,934	132,684	230,380

Current	17,990	38,197	95,552	177,829
Non-current	6,613	7,737	37,132	52,551

(i) The taxes paid in installments are presented below:

	Parent Company		Consolidated	
	03/31/2025	12/31/2024	03/31/2025	12/31/2024
Municipal	-	941	82	1,141
Federal	18,716	19,301	100,365	110,872
Total	18,716	20,242	100,447	112,013

19. ACCOUNTS PAYABLE FOR ACQUISITIONS

Subsidiaries and associated companies acquired	Parent Company	
	03/31/2025	12/31/2024
Centro Paulista de Oncologia S.A.	2,840	2,761
Núcleo de Oncologia da Bahia S.A.	12,747	20,564
Aliança Instituto de Oncologia S.A.	36,973	36,494
Onco Vida Instituto Especializado de Oncologia Clínica S.A.	19,931	19,669
Oncocentro Imagem Serviços Médicos Ltda.	14	14
Idengene Medicina Diagnóstica S.A.	478	11,719
Centro Brasileiro de Radioterapia Oncologia e Mastologia - CEBROM Ltda.	8,093	8,050
CTR - Centro de Tratamento Radioterápico Ltda.	2,417	2,182
Specialized Medical Treatment Company	-	920
Total	83,493	102,373
Current	12,236	21,481
Non-current	71,257	80,892

Subsidiaries and associated companies acquired	Consolidated	
	03/31/2025	12/31/2024
Multihemo Serviços Médicos S.A.	54,874	55,323
Hospital de Oncologia do Méier S.A.	8,466	8,221
Instituto Materno Infantil de Minas Gerais S.A.	27,595	26,916
Centro Paulista de Oncologia S.A.	2,840	2,761
CPO – Centro Paraibano de Oncologia S.A.	18,523	17,870
Hematológica – Clínica de Hematologia S.A.	22,332	21,712
Centro Brasileiro de Radioterapia Oncologia e Mastologia - CEBROM Ltda.	8,228	8,050
CTR - Centro de Tratamento Radioterápico Ltda.	2,282	2,182
CAM/CLION Group	20,155	30,818
Complexo Hospitalar Uberlândia S.A.	12,268	14,926
UMC Imagem Ltda. and Instituto do Coração do Triângulo Mineiro Ltda.	973	945
Medsir	-	965
Clínica de Mastologia da Bahia S.A.	801	714
Aliança Instituto de Oncologia S.A.	37,145	36,663
Onco Vida Instituto Especializado de Oncologia Clínica S.A.	20,188	19,925
Cardiomobile Cardiologia Móvel Ltda.	556	546
Instituto Paulista de Oncologia e Cuidados Paliativos Ltda	2,703	2,650
Onkos Participações Oncologia Ltda	38,179	36,732
Núcleo de Oncologia da Bahia S.A.	12,747	20,628
Oncoclínicas Participações Minas Gerais S.A.	3,621	3,517
Utraimagem Ltda	1,929	2,552
Giordani Camicia Serviços Médicos Ltda – Kaplan Uruguaiana	648	636
Oncohemato Recife Ltda.	119,137	116,802

Specialized Medical Treatment Company	-	920
Total	416,190	432,974
Current	148,429	85,494
Non-current	267,761	347,440

The balance of accounts payable for acquisition can be classified according to the following breakdown:

	Parent Company	
	03/31/2025	12/31/2024
Accounts payable from acquisition of interest	11,001	22,885
Put options (a)	12,747	20,564
Earnouts (b)	59,745	58,924
Total acquisitions payable	83,493	102,373
	Consolidated	
	03/31/2025	12/31/2024
Accounts payable from acquisition of interest	197,499	206,872
Put options (a)	20,990	31,600
Earnouts (b)	197,701	194,502
Total acquisitions payable	416,190	432,974

(a) Put options are provisions that force the buyer to acquire additional portions of shares at a future time under previously agreed conditions in contract.

(b) Earnouts are values linked to future performance targets of the acquired company. These targets may be related to revenues, profits or other performance indicators as contracts.

The accounts payable for acquisitions of Companies include the Purchase and Sale Agreements, and these amounts incur financial charges based on the change of the 100% CDI and/or IPCA and IGP-M rates.

The Company, in certain business combination processes, established contingent consideration clauses, which were determined based on the respective fair values, whose amount as of March 31, 2025 is R\$ 205,944 (R\$ 205,474 as of December 31, 2024).

Changes in accounts payable for acquisitions are as follows:

	Parent Company	Consolidated
Balance at December 31, 2023	468,473	592,487
Additions	11	307,962
Interest incurred	2,174	10,618
Adjustment to present value (i)	98	1,439
Adjustment to fair value (i)	674	1,511
Payment of principal	(20,351)	(175,801)
Payment of financial charges	-	(2,732)
Balance at March 31, 2024	451,079	735,484
Balance at December 31, 2024	102,373	432,974
Interest incurred	211	4,990
Discounts obtained	-	(321)
Exchange-rate change	-	(56)
Adjustment to present value (i)	67	998
Adjustment to fair value (i)	2,417	1,947

Payment of principal	(21,575)	(21,005)
Payment of financial charges	-	(3,337)
Balance at March 31, 2025	83,493	416,190

(i) Refers to adjustment to present value and adjustment to fair value of considerations assumed in business combinations.

Settlement flow	Parent Company	Consolidated
2025	7,867	136,688
2026	24,110	211,267
2027	3,663	18,754
2028	47,853	48,940
>2029	-	541
Total	83,493	416,190

20. OTHER LIABILITIES

Description	Parent Company		Consolidated	
	03/31/2025	12/31/2024	03/31/2025	12/31/2024
Exclusivity right (a)	4,733	4,990	27,247	29,502
Redemption of shares (c)	113	113	7,766	11,289
Partnership payable CSSJ	-	-	16,970	16,970
HSI operation	-	-	2,420	4,385
Obligation payable - Fundação Ary	322	313	322	313
Dana Farber (b)	53,972	58,806	53,972	58,806
Salto Itu (d)	-	-	13,142	12,752
Other accounts payable	7,465	9,250	17,625	15,500
Total	66,605	73,472	139,464	149,517
Current	22,533	24,652	71,495	73,418
Non-current	44,072	48,820	67,969	76,099

- a) Balance payable referring to the exclusivity right of medical services, whose purpose is to maintain the staff of professionals with excellence in medical services and market reference as contracts entered into among the parties.
- b) Balance payable referring to the intangible assets recognized pursuant to the contract with Dana Farber Institute.
- c) Balance payable for the redemption of shares, referring to the shareholders' agreement, in which the Oncoclínicas Group approves the redemption of all preferred shares, with the consequent cancellation of said shares, without a reduction in capital, as well as the extinction of the class of redeemable preferred shares.
- d) Balance payable relating to an agreement with Unimed Salto / Itu ("Unimed Salto Itu") for the provision of outpatient medical oncology services and immune-mediated systemic therapies for a period of 30 years.

21. PROVISION FOR TAX, LABOR AND CIVIL RISKS

The Oncoclínicas Group records provision to face its potential liabilities. Based on information from its legal advisors, on the analysis of these issues and considering the likelihood of loss in each lawsuit, a provision was formed, which is considered sufficient to cover possible losses for which cash outflows are likely.

The provision for risks was as follows:

	Parent Company		Consolidated	
	03/31/2025	12/31/2024	03/31/2025	12/31/2024
Civil	7	9	22,876	23,326
Tax	9,426	9,426	17,397	17,397
Labor	441	783	9,031	10,184
	9,874	10,218	49,304	50,907

Civil provision is mostly related to indemnity requests of pain and suffering and property damages claimed by patients as a result of the provision of services.

Provision of a labor nature arises mainly from employee complaints, mostly related to claims for unhealthy work premiums, overtime claims and third-party lawsuits requesting a subsidiary conviction.

The Group recorded R\$ 31,216 referring to lawsuits related to the business combination, whose respective triggering events are prior to the acquisition date of said subsidiary by the Oncoclínicas Group. The total amount of said claims is payable by the sellers to the Group and, therefore, the recognition of this amount was made against the indemnity asset during the measurement period, as provided for by IFRS 3/CPC 15.

	Parent Company	Consolidated
Balance at December 31, 2023	82	61,618
Restatement of indemnifiable asset	142	(1,047)
Reversal of provision	(2)	(71)
Formation	47	349
Balance at March 31, 2024	269	60,849
Balance at December 31, 2024	10,218	50,907
Restatement of indemnifiable asset	-	1,343
Reversal of provision	(424)	(4,813)
Formation	80	1,867
Balance at March 31, 2025	9,874	49,304

The Oncoclínicas Group monitors all administrative and legal proceedings in which figures as "plaintiff" or "defendant" and backed by the opinion of its legal advisors, classifies lawsuits according to the likelihood of loss. Analyses are conducted periodically on the jurisprudential trends and trial status, and, if necessary, reclassification of the risks of these proceedings is carried out.

Possible losses, not provisioned

The Group is party to tax, civil and labor lawsuits, involving loss risks classified as possible by Management, based on the evaluation of its legal advisors. No provision was recorded as the breakdown and estimate below:

	Parent Company		Consolidated	
	03/31/2025	12/31/2024	03/31/2025	12/31/2024
Civil (i)	14,552	4,013	82,818	59,852
Labor (ii)	2,550	4,338	29,662	25,271
Tax (iii)	1,109	2,520	92,764	32,457
	18,211	10,871	205,244	117,580

(i) Civil provision is mostly related to indemnity pain and suffering and property damages claimed by patients as a result of the provision of services. There is no individually relevant lawsuit.

(ii) Provision of a labor nature arises mainly from employee complaints, mostly related to claims for unhealthy work premiums, overtime claims and third-party lawsuits requesting a subsidiary conviction. There is no individually relevant lawsuit.

(iii) Tax provision is related to the collection of allegedly unpaid or underpaid taxes and among them, we highlight the following:

Assessment filed against the Company in the Municipality of Rio de Janeiro regarding alleged underpayment of the Service Tax (ISS). The assessment was challenged in the administrative level with a possible chance of success (70%) and its enforceability has been suspended.

In 2025, the Brazilian Federal Revenue Service assessed an investee of the Company, alleging non-payment of social security contributions and third-party contributions applicable to the payroll of employees, plus fines and interest. The amount involved is approximately R\$ 60,000. The assessments have been challenged in the administrative level, with a possible chance of success (70%), and their enforceability has been suspended. In the event of an unfavorable decision, both causes will be classified as indemnifiable losses.

Considering the complexities of the lawsuits, as well as the Brazilian legal system, the Company is not able to estimate with reasonable accuracy the term of the decision and whether there will be any disbursement related to administrative proceedings and lawsuits.

As of March 31, 2025 and December 31, 2024, judicial deposits are stated as follows:

	Parent Company		Consolidated	
	03/31/2025	12/31/2024	03/31/2025	12/31/2024
Civil	-	-	190	190
Tax (i)	21,688	21,889	65,709	61,901
Labor (ii)	711	682	4,426	4,074
Total	22,399	22,571	70,325	66,165

The Company made judicial deposits including legal disputes related to tax, civil and labor matters, in which we highlight the following deposits:

(i) Judicial deposits in writs of mandamus that aim to ensure the inclusion of debts in the Incentivized Self-Adjustment of the Brazilian Federal Revenue Service, governed by Law 14740/2023. The total amount deposited for this discussion is R\$ 52,441;

Judicial deposits in proceedings for payment into court that aim to avoid the collection of ICMS tax higher than the amount due on the imports of surgical equipment, the total amount of the deposits reaches R\$ 4,530;

Partial deposit of PIS/COFINS and Income Tax/CSLL in the records of proceedings that discuss tax theories aiming to reduce the calculation basis of said taxes, totaling R\$ 6,023 in deposit;

(ii) Several judicial deposits referring to labor lawsuits in progress.

22. SHAREHOLDERS' EQUITY

(a) Capital

As of March 31, 2025, the Company's capital is R\$ 3,147,024 (R\$ 3,147,024 as of December 31, 2024), represented by six hundred and fifty-one million, seven hundred and fifty-six thousand, three hundred and thirteen (651,756,313) common shares (651,756,313 common shares as of December 31, 2024).

As of March 31, 2025 and December 31, 2024, the shareholding structure is comprised of:

Shareholder	Position as of March 31, 2025		Position on December 31, 2024	
	Voting capital	Common shares	Voting capital	Common shares
Josephina I	-	-	15.79%	102,914,808
Josephina II	4.97%	32,384,734	4.97%	32,384,734
Bruno Ferrari	8.41%	54,843,186	8.41%	54,843,186
Banco Master	19.90%	129,679,374	19.90%	129,679,374
Management	0.70%	4,539,211	0.70%	4,539,211
Josephina III	31.84%	207,498,778	16.05%	104,583,970
Latache	10.19%	66,402,315	-	-
Treasury	2.91%	18,963,632	2.91%	18,963,632
Free Float	21.09%	137,445,083	31.28%	203,847,398
Total	100.00%	651,756,313	100.00%	651,756,313

b) Treasury shares

The total number of treasury shares on March 31, 2025 and December 31, 2024, is as follows:

	March 31, 2025	December 31, 2024
Unit price	5.35114	5.35114
Number of shares	18,963,632	18,963,632
Total	94,468	94,468

c) Share-based payment

The Company has an executive/employee compensation program that consists of granting rights to share appreciation ("Stock Options").

The Stock Option Plan establishes the terms and conditions for the granting of common shares issued by the Company, subject to certain conditions, to the administrators, employees and service providers of the Company, or of other companies under its control.

Share-based and share-settled payments to Company's employees and executives are measured at the fair value of equity instruments on the grant date. The determination of the fair value of the call options granted to all beneficiaries of the program considers the development of specific estimates of the assumptions for calculating the fair values of these instruments, including the price of the underlying share, the exercise price of the option, the free market interest rate, the dividend rate, volatility, the lifetime of the instruments and the grace period. The Black & Scholes method was adopted by the company to value these instruments.

For measurement and recognition purposes, the Company accessed the criteria established by CPC 10(R1)/IFRS 2 considering the program as an equity settlement, with the balance held in liabilities arising from tax and social security obligations that will be paid by the Company in cash.

The Company recognized in the shareholders' equity totaling R\$ 3,364 as of March 31, 2025 (R\$ 4,944 as of March 31, 2024) derived from options vested in the period.

d) Acquisition of equity interest with non-controlling shareholders and transactions among partners

Refers to the exercise of call options granted by minority shareholders, representing 3.17% of the capital of the company Núcleo de Oncologia da Bahia S.A. The transaction generated a gain of R\$ 2,527 in the shareholders' equity balances of the Parent Company and a loss of R\$ 2,527 in the shareholders' equity of non-controlling shareholders.

e) Transactions among partners

In January 2025, Oncoclínicas capitalized an advance for a future capital increase in the investee NOB, with R\$ 1.00 allocated to the Capital account and R\$ 20,038 allocated to the Capital Reserve account (Capital Reserve Premium on Subscription). The transaction resulted in a loss of R\$ 3,973 in the shareholders' equity of the Parent Company and a gain of R\$ 3,973 in the shareholders' equity of non-controlling shareholders.

Furthermore, in January 2025, there was a capital contribution from the Company to the foreign investee Medica Scientia Innovation Research. The transaction generated a loss in the Parent Company's shareholders' equity of R\$ 2,320.

23. REVENUES

The reconciliation between gross sales and net revenue is as follows:

Description	Parent Company	
	03/31/2025	03/31/2024
Gross revenue:		
Health services	277,177	259,979
Sales taxes and other deductions:		
PIS on sales	(1,742)	(1,769)
COFINS on sales	(8,038)	(7,625)
ISS on sales	(6,837)	(5,910)
Provision for expected credit loss and disallowance	(4,896)	(3,667)
	(21,513)	(18,971)
Net revenue	255,664	241,008
Description	Consolidated	
	03/31/2025	12/31/2024
Gross revenue:		
Health services	1,658,058	1,620,818
Sales taxes and other deductions:		
PIS on sales	(10,146)	(11,087)
COFINS on sales	(46,886)	(49,936)
ISS on sales	(42,726)	(39,247)
Provision for expected credit loss and disallowance	(65,144)	(61,882)
	(164,902)	(162,152)
Net revenue	1,493,156	1,458,666

Gross revenue includes revenue to be billed referring to services provided but not processed to healthcare insurance companies. These services are recognized in income (loss) based on the stage of completion of the service rendered on the reporting date of Financial Information. Moreover, gross revenue includes contracts with operators that are linked to fixed remuneration for each cancer patient over an agreed treatment period. The entry has its contra entry recorded in trade accounts receivable in compliance with current accounting standards.

In the three-month period ended March 31, 2025, the Company's gross revenue is composed of sundry clients, with only one of them having an individual participation exceeding 15%. The other clients, considered

individually, represented percentages lower than 11% of the Company's net revenue. Furthermore, the two customers with the highest concentration combined account for less than 33% of the Company's total gross revenue.

24. COSTS AND EXPENSES BY TYPE

	Parent Company	
	03/31/2025	03/31/2024
Medical and medication costs	(182,136)	(108,657)
Personnel, charges and bonus	(64,467)	(86,268)
Stock option plan expense	(4,007)	(5,774)
Expenses with outsourced services	(74,227)	(25,585)
Rental of properties and condominiums	(1,041)	(1,189)
Infrastructure expense	(2,668)	(2,377)
Travel expenses	(2,206)	(1,816)
Use and consumption	(832)	(803)
Communications expenses	(7,467)	(5,226)
Depreciation and amortization	(23,283)	(17,269)
Provision to tax, labor, civil risks	344	(45)
CSO - Apportionment of expenses (i)	102,473	97,955
Other revenues (expenses)	(21,076)	(8,176)
	(280,593)	(165,230)
Cost of services rendered	(192,442)	(116,200)
Administrative expenses	(72,546)	(46,404)
Other operating revenues (expenses)	(15,605)	(2,626)
Total	(280,593)	(165,230)

	Consolidated	
	03/31/2025	03/31/2024
Medical and medication costs	(936,140)	(849,707)
Personnel, charges and bonus	(216,912)	(231,942)
Stock option plan expense	(4,007)	(5,774)
Outsourced service expenses	(147,085)	(74,661)
Rental of properties and condominiums	(4,474)	(6,366)
Infrastructure expenses	(15,954)	(14,055)
Travel expenses	(4,961)	(4,997)
Use and consumption	(13,021)	(13,477)
Communications expenses	(7,809)	(6,614)
Depreciation and amortization	(74,109)	(67,649)
Provision to tax, labor, civil risks	2,946	(278)
Other revenues (expenses)	(30,007)	(16,350)
	(1,451,533)	(1,291,870)
Cost of services rendered	(1,080,912)	(976,386)
Administrative expenses	(358,844)	(316,967)
Other operating revenues (expenses)	(11,777)	1,483
Total	(1,451,533)	(1,291,870)

- i) Apportionment: this is the apportionment of costs and expenses of the Oncoclínicas Group's shared service center, centralized in the Parent Company and apportioned to its subsidiaries, according to criteria defined by management.

25. FINANCIAL INCOME (LOSS)

	Parent Company	
	03/31/2025	03/31/2024
Financial revenues		
Yields from interest earning bank deposits	37,889	108
Discounts obtained	16	345
Interest receivable on loans with related parties (Note 29)	25,229	13,733
Derivative financial liability instrument ("swap")	29,136	3,336
Positive exchange-rate changes	13,909	1
PIS/COFINS on financial revenue	(2,984)	(647)
Adjustment to fair value	10,668	-
Other financial revenues	1,032	2,474
	114,895	19,351
Financial expenses		
Expenses with interest on loans	(35,685)	(63,602)
Interest on debenture expenses	(60,464)	(23,616)
Tax on financial operations (IOF)	(1,905)	(407)
Expenses with interest on acquisitions	(211)	(2,174)
Bank fees	(28)	(208)
Foreign-exchange loss	(1,742)	(2,328)
Discounts granted	(295)	(40)
Interest on liabilities from loans with related parties	(6,654)	(7,406)
Derivative financial instrument (liabilities) ("swap")	(31,572)	(27,921)
Interest on lease liabilities	(1,640)	(481)
Adjustment to present value	(854)	(880)
Adjustment to fair value	(47,887)	(674)
Other financial expenses	(4,275)	(6,371)
	(193,212)	(136,108)
Financial income (loss)	(78,317)	(116,757)
	Consolidated	
	03/31/2025	03/31/2024
Financial revenues		
Yields from interest earning bank deposits	48,610	8,663
Discounts obtained	736	3,263
Interest receivable on loans with related parties (Note 29)	823	221
Derivative financial liability instrument ("swap")	29,136	3,798
Positive exchange-rate changes	13,968	1,137
PIS/COFINS on financial revenue	(5,004)	(2,206)
Adjustment to fair value	13,485	-
Other financial revenues	7,013	4,689

	<u>108,767</u>	<u>19,565</u>
Financial expenses		
Expenses with interest on loans	(51,961)	(79,955)
Interest on debenture expenses	(85,028)	(56,497)
Tax on financial operations (IOF)	(5,478)	(2,743)
Expenses with interest on acquisitions	(4,990)	(10,035)
Bank fees	(258)	(483)
Foreign-exchange loss	(1,798)	(4,680)
Discounts granted	(2,527)	(387)
Interest payable from related party loans	-	(565)
Derivative financial instrument (liabilities) ("swap")	(31,572)	(27,921)
Interest on lease liabilities	(15,643)	(9,905)
Adjustment to present value	(2,152)	(2,509)
Adjustment to fair value	(50,234)	(1,511)
Other financial expenses	(5,294)	(14,272)
	<u>(256,935)</u>	<u>(211,463)</u>
Financial income (loss)	<u>(148,168)</u>	<u>(191,898)</u>

26. EARNINGS PER SHARE

Basic earnings per share are calculated by dividing income or loss attributable to Company's shareholder, by the weighted average number of common shares issued during the period, less the common shares purchased by the Company and held as treasury shares.

As of March 31, 2025, the Company has 14,785,191 thousand potential common shares referring to subscription warrants resulting from the business combination with the company Unity Participações, for which their exercise is not linked to contingent conditions, being considered for the basic earnings (loss) per share.

Diluted earnings per share are calculated by adjusting to weighted average quantity of outstanding common and preferred shares, assuming conversion of all common shares that would possibly provoke dilution.

As of March 31, 2025 and 2024, the Company had shares related to the share-based payment program, as mentioned in Note 22. Considering the net income (loss) calculated for the three-month period ended March 31, 2025, which recorded a loss, such instruments were considered anti-dilutive and, therefore, were not included in the calculation of diluted earnings (loss) per share. For the year 2024, the aforementioned instruments were included in the determination of diluted earnings per share.

	<u>03/31/2025</u>	<u>03/31/2024</u>
Income (loss) attributable to controlling shareholders		
Basic earnings (losses) per share:	(146,494)	9,592
Weighted average number of outstanding shares and subscription warrant	597,377,413	545,915,906
Basic earnings (losses) per share - in reais (R\$)	<u>(0.2511)</u>	<u>0.0110</u>
Diluted earnings (loss) per share:		
Weighted average number of shares outstanding, subscription warrants and shares of the share-based payment program	597,377,413	561,734,058
Diluted earnings (losses) per share – in reais (R\$)	<u>(0.2511)</u>	<u>0.0107</u>

27. INCOME TAX AND SOCIAL CONTRIBUTION

The Company and most of its subsidiaries elect for the taxable income regime, the other subsidiaries elect for the deemed income regime.

Income tax charges are as follows:

	Consolidated	
	03/31/2025	03/31/2024
Companies electing for the deemed income (a)	7,563	10,862
Companies electing for the taxable income (b)	32,404	(55,554)
	39,967	(44,692)

(a) Income tax charges - Companies subject to deemed income regime:

	Consolidated	
Revenues	03/31/2025	03/31/2024
Services	262,897	223,728
Total	262,897	223,728
Income tax assumption – 8%	21,032	17,898
Social contribution assumption – 12%	31,548	26,487
Other revenues	4,419	9,639
Income tax expense	3,818	4,131
Social contribution expense	3,237	3,284
Additional (10% on the surplus)	508	3,447
Total income tax and social contribution expense	7,563	10,862

(b) Income tax charges - Companies subject to taxable income regime:

	Parent Company	
	03/31/2025	03/31/2024
Income (loss) before income tax and social contribution	(137,184)	(45,431)
Nominal rate	34%	34%
Nominal revenue (expense)	46,643	15,447
Adjustments to nominal expense (revenue)		
Equity in net income of subsidiaries	(11,539)	(1,514)
Other permanent differences, net	(3,751)	(631)
Tax credits formed (*)	-	47,103
Tax credits not formed (**)	(40,663)	(5,382)
Effective revenue (expense)	(9,310)	55,023
Current	(18,106)	(4)
Deferred	8,796	55,027

	Consolidated	
	03/31/2025	03/31/2024
Income (loss) before income tax and social contribution	(92,007)	(25,103)
Nominal rate	34%	34%
Nominal revenue (expense)	31,282	8,535

	Parent Company	
	03/31/2025	03/31/2024
Adjustments to nominal expense (revenue)		
Equity in net income of subsidiaries	4,943	-
Other permanent differences, net	(2,001)	(1,903)
Effect of taxation of subsidiaries based on presumed income	13,771	6,296
Tax credits formed	3,148	47,103
Tax credits not formed (*)	(91,110)	(15,339)
Effective revenue (expense)	(39,967)	44,692
Current	(67,140)	(34,852)
Deferred	27,173	79,544

(*) The balances of tax loss, negative social contribution basis and temporary differences calculated in previous years and in the three-month period ended March 31, 2025 are based on the tax planning carried out by the Company, considering a 10-year term. Therefore, said balances are not supported by the Company's recoverability plan and, thus, no tax credits have been recognized for these amounts.

Deferred income tax asset

Deferred tax arising from temporary additions and exclusions, and tax loss and negative basis of social contribution, is broken down as follows:

	Parent Company		Consolidated	
	03/31/2025	12/31/2024	03/31/2025	12/31/2024
Tax loss and negative basis of social contribution	201,061	192,264	319,831	299,845
Swap	12,208	12,208	13,289	13,289
Provision for expected credit losses and disallowance	1,934	1,934	41,808	37,265
Provision on profit sharing	7,764	7,764	11,111	11,298
Provision for suppliers and risks	3,850	3,850	5,983	8,089
Provision for bonus	5,447	5,447	5,164	7,013
Leases	958	958	24,709	11,435
Surplus and deficit – Hospital Marcos Moraes	-	-	1,367	1,367
Adjustment to recoverable value of assets	57,335	57,335	57,335	57,335
Adjustment to present value and adjustment to fair value	1,935	1,935	11,003	12,251
Funding cost of loans	2,761	2,761	3,100	3,306
Self-regularization (*)	3,606	3,606	50,845	50,845
Total	298,859	290,062	545,545	513,338
Lease liabilities	-	(1,870)	(452)	(5,248)
Total	298,859	288,192	545,093	508,090

(*) Refers to deferred income tax and social contribution credits on tax losses and negative CSLL bases that were included in the Self-Regulation Program mentioned in Note 19. These credits will be offset against the amounts provisioned in the caption of tax obligations as soon as the Brazilian Federal Revenue Service approves the Company's adherence to said program.

Temporary additions and exclusions

The Oncoclínicas Group calculates the deferred income tax and social contribution on tax losses, negative basis of social contribution and temporary differences, under the rates of 25% and 9%, respectively.

The deferred tax asset is recognized to the extent that it is probable that taxable income will be available to be realized, based on projections of profit or loss that are prepared in line with future economic scenarios, and may suffer fluctuations.

Based on projections of future taxable income and compliance with CPC 32, in 2023, the Company recognized the deferred assets on tax losses and negative bases of social contribution and temporary differences, which will be reviewed at each balance sheet date and, if necessary, will be reduced to the extent that their realization is no longer likely.

The recognized tax credits are expected to be realized as shown in the following table:

Realization estimate	Parent Company		Consolidated	
	03/31/2025	12/31/2024	03/31/2025	12/31/2024
2025	30,131	53,235	153,932	165,670
2026	17,400	61,801	41,819	81,222
2027	23,730	87,851	34,853	100,396
2028	44,781	26,451	58,874	37,264
2029	67,244	58,854	83,934	123,538
2030 onwards	115,573	-	171,682	-
Total	298,859	288,192	545,094	508,090

(c) Deferred income tax liabilities – Consolidated

	Consolidated	
	03/31/2025	12/31/2024
Deferred capital gain/loss on property, plant and equipment related to business combinations	7,070	7,070
Deferred tax use of goodwill	38,697	34,116
Total	45,767	41,186

28. FINANCIAL INSTRUMENTS

(a) Financial risk factors

The Oncoclínicas Group is exposed to the following financial risks: credit risk, liquidity risk and market risk. The Group's Management has full responsibility for the establishment and supervision of the Company's risk management framework.

The risk management framework of the Oncoclínicas Group was established to identify and analyze risks to which the Oncoclínicas Group is exposed, to set risk limits and appropriate controls, and to monitor risks and compliance with limits. The Oncoclínicas Group seeks to develop, upon its training and management procedures, a discipline and control environment in which all employees are aware of their assignments and obligations.

(i) Credit risk

Credit risk is the risk of the Oncoclínicas Group incurring losses due to a client or financial instrument counterparty and resulting from failure in complying with contract obligations. The risk basically derives from balances in financial institutions (checking account, interest earning bank deposits, securities and derivative financial instruments), trade accounts receivable, accounts receivable for the disposal of equity interests, among others.

Credit risk exposure

The book values of financial assets classified as loans and receivables represent the maximum credit exposure. The maximum credit risk exposure at the end of the three-month period ended March 31, 2025

and twelve-month period ended December 31, 2024 is as follows:

	Note	Parent Company		Consolidated	
		03/31/2025	12/31/2024	03/31/2025	12/31/2024
Cash and cash equivalents	4	171,512	228,812	550,519	550,744
Securities	5	792,716	1,040,032	1,107,895	1,467,551
Derivative instruments	28	25,850	39,207	25,850	39,207
Trade accounts receivable	6	435,552	441,540	2,493,204	2,434,594
Judicial deposits	21	22,399	22,571	70,325	66,165
Sales of ownership interest	9	10,308	10,051	11,216	10,975
Indemnity assets	9	20,427	9,426	46,885	50,084
Related parties	29	1,101,247	1,095,803	20,513	20,664
Total		2,580,011	2,887,442	4,326,407	4,639,984

Cash and cash equivalents, securities and derivative financial instruments

Balances held in checking accounts, interest earning bank deposits, securities and derivative financial instruments represent the maximum exposure to the credit risk of these balances.

Trade accounts receivable

The Oncoclínicas Group's exposure to credit risks is influenced mainly by the individual characteristics of each client/health care plan. However, Management considers the history of each customer in its analysis, based on the default risk.

The management of this risk is carried out to guarantee the total receipt of revenue from agreements. The risk is mitigated by the widespread customer portfolio and the possibility of discontinuance of services to the beneficiaries of health insurance plans after a given default period.

Impairment losses

	Note	Parent Company		Consolidated	
		03/31/2025	12/31/2024	03/31/2025	12/31/2024
Trade accounts receivable	6	455,918	456,918	2,791,820	2,671,922
Provision for expected losses and disallowance	6	(20,366)	(15,378)	(298,616)	(237,328)
		435,552	441,540	2,493,204	2,434,594

% of provision on the balances of trade accounts receivable

4.47%

4.42%

10.70%

8.60%

As of March 31, 2025 and December 31, 2024, the provision for expected credit losses refers mainly to disallowances identified by health insurance plans during the year, and the low expectation of receipt according to the receivable expired period, except for credits guaranteed by legal instruments, as mentioned in Note 06. The Company believes that the provisioned amount and the disclosed expected losses are sufficient for the risks inherent to the receivables.

The assessment of the amount of past-due trade accounts receivable not subject to impairment is constantly monitored by the sales managers of each healthcare center, to identify amounts that may not be collected. In this case, an provision will be recognized at the amounts of the respective expected losses.

Other financial assets

Balances arising from amounts receivable for disposal of equity interests represent the maximum exposure to the credit risk of these balances.

(ii) Liquidity risk

Liquidity risk is the risk of the Group not having sufficient net funds to honor its financial commitments due to a time or volume mismatch between foreseen receipts and payments. The Oncoclínicas Group's approach in liquidity management is to guarantee, as much as possible, a sufficient liquidity to perform its obligations upon maturity, under normal and stress conditions, without causing unacceptable losses or with a risk of sullyng the Oncoclínicas Group's reputation.

The table below analyzes the Oncoclínicas Group's non-derivative liabilities and derivative financial liabilities which are settled on a net basis by the Oncoclínicas Group, per maturity brackets, corresponding to remaining period between the balance sheet date and contract maturity date. Derivative financial liabilities are included in the analysis if their contract maturities are essential to understand cash flows. Amounts disclosed in the table are contracted undiscounted cash flows.

				Parent Company					
				Future payment flow					
	Note	03/31/2025	Total Future flow	2025	2026	2027	2028	2029	2030 onwards
Suppliers	14	189,554	189,554	189,554	-	-	-	-	-
Loans and financing	15	1,864,561	2,774,341	259,120	305,759	457,263	366,334	315,878	1,069,987
Debentures	16	1,812,835	2,593,611	247,507	307,745	894,330	234,121	909,908	-
Derivative financial instruments	28	90,829	95,283	28,874	37,493	31,821	32,306	33,392	(68,603)
Partnerships	20	322	1,325	325	-	-	-	-	-
Redemption of shares	20	113	114	114	-	-	-	-	-
Exclusivity right	20	4,733	5,468	1,795	1,583	1,250	840	-	-
Dana Farber	20	53,972	71,249	9,883	11,295	11,295	11,295	11,295	16,186
Related parties	29	470,097	511,259	79,793	431,466	-	-	-	-
Accounts payable for acquisitions		83,493	105,431	8,055	25,358	4,728	67,290	-	-
Total		4,570,509	6,346,635	825,020	1,120,699	1,400,687	712,186	1,270,473	1,017,570

				Consolidated					
				Future payment flow					
	Note	03/31/2025	Total future flow	2025	2026	2027	2028	2029	2030 onwards
Suppliers	14	994,297	994,297	994,297	-	-	-	-	-
Loans and financing	15	2,333,722	3,321,073	365,526	675,080	498,414	385,412	321,752	1,074,889
Derivative financial instruments	28	90,829	95,283	28,874	37,493	31,821	32,306	33,392	(68,603)
Debentures	16	2,492,765	3,472,130	516,607	565,815	1,120,169	359,631	909,908	-
Partnerships	20	32,857	35,691	19,218	16,473	-	-	-	-
Exclusivity right	20	27,247	31,223	8,649	8,651	5,630	1,006	840	6,447
Redemption of shares	20	7,766	8,153	-	3,948	4,205	-	-	-
Dana Farber	20	53,972	71,249	9,883	11,295	11,295	11,295	11,295	16,186
Related parties	29	6,670	7,605	-	7,605	-	-	-	-
Accounts payable for acquisitions	19	416,190	460,314	139,133	230,783	21,121	68,630	647	-
Total		6,456,315	8,497,018	2,082,187	1,557,143	1,692,655	858,280	1,277,834	1,028,919

(i) Market risk

Cash flow or fair value risk associated to the interest rate

The interest rate risk of the Oncoclínicas Group arises from loans and financing, debentures, balances of loans, and balances payable related to long-term company acquisitions.

Oncoclínicas Group monitors its exposure to benchmark interest rate fluctuation, arising from debt instruments, and conducts sensitivity tests using different rates during its financial planning to ensure liquidity even during scenarios with higher interest rate fluctuation.

Sensitivity analysis of interest

On March 31, 2025, the Company's exposure occurs due to financial assets and liabilities that are subject to the following indicators:

Indexes	Current scenario	Probable Scenario I	Scenario II +25%	Scenario III +50%
CDI rate (p.a.)	14.90%	14.90%	18.63%	22.35%
IGPM rate (p.a.)	5.14%	4.92%	6.43%	7.71%
IPCA Rate (p.a.)	5.65%	5.57%	7.06%	8.48%
TJLP	8.65%	8.65%	10.81%	12.98%

For the sensitivity analysis of interest, the benchmark rates for 2025, reported in Focus report, disclosed by the Central Bank of Brazil (<https://www.bcb.gov.br>) as of April 17, 2025 were used as probable scenario (Scenario I). While scenarios II and III take into account an increase in this rate of 25% and 50%, respectively. The results are as follows:

Assets	Index	Book value	Probable Scenario I	Parent Company	
				Scenario II 25%	Scenario III 50%
Interbank funds applied	CDI	156,342	156,342	162,166	167,989
Securities	CDI	792,716	792,716	822,245	851,773
Sales of ownership interest	CDI	10,308	10,308	10,692	11,076
Related parties	CDI	746,211	746,211	774,007	801,804
		1,705,577	1,705,577	1,769,110	1,832,642
Effect from gain (loss)			-	63,533	127,065

Liabilities	Index	Book value	Probable Scenario I	Parent Company	
				Scenario II 25%	Scenario III 50%
CCB/Working capital	CDI	(167,392)	(167,392)	(173,628)	(179,864)
Cri	CDI	(1,471,678)	(1,471,678)	(1,526,498)	(1,581,318)
Law 4131	CDI	(169,697)	(169,697)	(176,018)	(182,339)
Debentures	CDI	(1,812,835)	(1,812,835)	(1,880,363)	(1,947,891)
Related parties	CDI	(470,097)	(470,097)	(487,608)	(505,119)
FINEP	TJLP	(55,794)	(55,794)	(57,001)	(58,207)
Acquisitions	IPCA	(67,414)	(67,360)	(68,366)	(69,318)
		(4,214,907)	(4,214,853)	(4,369,482)	(4,524,056)
Effect from gain (loss)			54	(154,575)	(309,149)
Effect from net gain (loss)			54	(91,042)	(182,084)

Assets	Index	Consolidated			
		Book value	Probable Scenario I	Scenario II	Scenario III
				25%	50%
Interbank funds applied	CDI	431,893	431,893	447,981	464,069
Securities	CDI	1,107,895	1,107,895	1,149,164	1,190,433
Sales of ownership interest	CDI	11,216	11,216	11,634	12,052
Related parties	CDI	20,513	20,513	21,277	22,041
		1,571,517	1,571,517	1,630,056	1,688,595
Effect from gain (loss)			-	58,539	117,078

Liabilities	Index	Consolidated			
		Current scenario	Probable Scenario I	Scenario II	Scenario III
				25%	50%
CCB/Working capital	CDI	(596,760)	(596,760)	(618,989)	(641,219)
Cri	CDI	(1,471,678)	(1,471,678)	(1,526,498)	(1,581,318)
Law 4131	CDI	(169,697)	(169,697)	(176,018)	(182,339)
Financing	CDI	(2,203)	(2,203)	(2,285)	(2,367)
Debentures	CDI	(2,492,765)	(2,492,765)	(2,585,620)	(2,678,476)
Acquisitions	CDI	(22,355)	(22,355)	(23,188)	(24,020)
FINEP	TJLP	(55,794)	(55,794)	(57,001)	(58,207)
Financing	IPCA	(21,861)	(21,844)	(22,170)	(22,479)
Acquisitions	IPCA	(349,853)	(349,573)	(354,795)	(359,736)
CCB/Working capital	IPCA	(772)	(771)	(783)	(794)
Acquisitions	IGPM	(27,595)	(27,534)	(27,949)	(28,305)
		(5,211,333)	(5,210,974)	(5,395,296)	(5,579,260)
Effect from gain (loss)			359	(183,963)	(367,927)
Effect from net gain (loss)			359	(125,424)	(250,849)

The Company considers that the 25% and 50% variation represents an appropriate sensitivity considering the historical variation of the respective indicators in the period analyzed.

(iv) Foreign exchange risk

The Company mainly operates in the domestic market and its receivables and payables are almost in full denominated in domestic currency. The Company has a risk management policy, which determines that agreements that may pose currency risk and may significantly affect the Company's Financial Information, must be subject to measures to hedge and mitigate such impact by Management.

In order to reduce its funding costs, the Company contracted loans in foreign currency. As a strategy to manage the foreign exchange risk, Oncoclínicas Group simultaneously carries out swap transactions under identical conditions in terms of amount, term and rate, swapping the exposure to Positive exchange-rate changes for the CDI change. Accordingly, the Company has no significant exposure to foreign exchange risk.

The Company has no risk of exchange exposure, since, when contracting this loan mentioned in foreign currency, a linked swap operation was contracted.

The fair value of these instruments on the date of Financial Information is as follows:

	Parent Company		Consolidated	
	03/31/2025	12/31/2024	03/31/2025	12/31/2024
<u>Derivative financial assets</u>				
Derivatives designated and effective as hedge instruments demonstrated at fair value:				
Interest rate swaps	8,859	19,325	8,859	19,325
Derivatives held for trading not assigned at fair value through profit or loss				
Interest rate swaps	16,991	19,882	16,991	19,882
	25,850	39,207	25,850	39,207
<u>Derivative financial liabilities</u>				
Derivatives designated and effective as hedge instruments demonstrated at fair value:				
Interest rate swaps	90,829	(106,002)	90,829	(106,002)
Derivatives held for trading not assigned at fair value through profit or loss				
Interest rate swaps	-	(1,044)	-	(1,044)
	90,829	(107,046)	90,829	(107,046)

Derivatives designated for hedge accounting

The Company has formally designated certain derivative financial instruments for hedge accounting purposes to hedge loans and financing. The type of hedge relationship applied to such instruments is the fair value hedge, which is used to offset variations resulting from changes in the fair value of the liability attributable to the specific risk.

Hedge

Company	Classification	Maturity	Index		Reference value	Curve value			Market value (book)			Gain (loss)
			Asset position	Liability position	Domestic	Asset position	Liability position	Gain (loss)	Asset position	Liability position	Gain (loss)	Curve X MTM
Parent Company	Fair value	03/03/2026	100% USD + 7.40%	100% CDI-CETIP + 1.8%	USD 6,073	23,470	(20,208)	3,262	23,238	(20,208)	3,030	232
Parent Company	Fair value	03/09/2026	100% USD + 7.36%	100% CDI-CETIP + 1.75%	USD 6,032	23,288	(20,173)	3,115	23,144	(23,173)	2,971	144
Parent Company	Fair value	03/17/2026	100% USD + 7.50%	100% CDI-CETIP + 1.75%	USD 5,979	23,054	(20,117)	2,937	22,975	(20,117)	2,858	79
Parent Company	Fair value	10/15/2030	100% IPCA + 7.1768%	100% CDI-CETIP + 1.60%	BLR 98,257	108,792	(104,179)	4,603	100,140	(104,179)	(4,039)	8,642
Parent Company	Fair value	10/17/2033	100% IPCA + 7.4342%	100% CDI-CETIP + 1.91%	BLR 82,387	91,311	(87,473)	3,838	82,153	(87,473)	(5,320)	9,158
Parent Company	Fair value	10/15/2030	12.60% P.A.	100% CDI-CETIP + 1.58%	BLR 601,762	634,651	(637,935)	(3,284)	556,465	(637,935)	(81,470)	78,186
						904,556	(890,085)	14,471	808,115	(890,085)	(81,970)	96,441
										Assets	8,859	
										Liabilities	(90,829)	

Fair value through profit or loss (not designated)

			Index		Reference value	Curve value			Market value (book)			Gain (loss)
Company	Classification	Maturity	Asset position	Liability position	Domestic	Asset position	Liability position	Gain (loss)	Asset position	Liability position	Gain (loss)	Curve X MTM
Parent Company	MTM	08/15/2029	IPCA + 6.7040	CDI + 1.1600	194,626	220,860	(197,617)	23,243	211,712	(205,238)	6,474	16,769
Parent Company	MTM	08/16/2032	IPCA + 6.8269	CDI + 1.3000	64,163	73,028	(65,162)	7,866	69,516	(68,777)	739	7,127
Parent Company	MTM	04/02/2025	100% USD + 7.16%	CDI + 1.8000	85,000	101,349	(90,581)	10,768	100,372	(90,564)	9,778	990
					343,789	395,237	(353,360)	41,877	381,600	(364,609)	16,991	24,886
											Assets	16,991
											Liabilities	-

(b) Capital management

The Company's objectives in managing its capital are to safeguard Oncoclínicas Group's business continuity capacity to offer return to shareholders and benefits to the other shareholders besides maintaining an optimal capital structure to reduce this cost.

In order to keep or adjust the capital structure, the Company may review the dividend payment policy, refund capital to the shareholders or, also, issue new shares or sell assets to reduce, for instance, the indebtedness level.

There were no changes in the Group's approach to the management of capital during the three-month period ended March 31, 2025. The Group manages capital requirements on an aggregate basis.

As of March 31, 2025 and December 31, 2024, the financial leverage ratios can be summarized as follows:

	Consolidated	
	03/31/2025	12/31/2024
Total loans and financing (Note 15)	2,333,722	2,469,099
Total derivative financial instruments (Note 28)	64,979	67,839
Total debentures (Note 16)	2,492,765	2,448,108
Total accounts payable for acquisition (Note 19)	416,190	432,974
Cash and cash equivalents (Note 4)	(550,519)	(550,744)
Securities (Note 05)	(1,107,895)	(1,467,551)
Total net debt	3,649,242	3,399,725
Total shareholders' equity	3,300,152	3,382,425
Total capital (shareholders' equity + net debt)	6,934,597	6,782,150
Financial leverage index - %	53%	50%

(c) Estimate of fair value through profit or loss

Financial instruments that are measured at fair value on balance sheet dates as determined by CPC 46 – Measurement of fair value follow this hierarchy:

Level 1: Evaluation of assets and liabilities based on prices quoted in active markets.

Level 2: Used for financial instruments not traded in active markets, incorporating additional techniques beyond Level 1 quoted prices.

Level 3: Valuation techniques for which the lowest significant input level is not observable.

Management considers that the book values of financial assets and liabilities measured at amortized cost are close to their fair values, except for balances related to related parties, loans, financing, and debentures.

Financial assets and liabilities measured at fair value include derivative financial instruments (Level 2) and contingent considerations, options assumed in acquisitions, and liabilities in partnership agreements (Level 3). The company uses the discounted cash flow technique, based on revenue growth, costs, expenses, and discount rate.

(d) Financial instruments by category

Financial instruments	Measurement	Parent Company			
		Book value	Fair value	Book value	Fair value
		03/31/2025	03/31/2025	12/31/2024	12/31/2024
Financial assets					
Cash and cash equivalents	Amortized cost	171,512	(*)	228,812	(*)
Securities	Amortized cost	792,716	(*)	1,040,032	(*)
Derivative instruments	Fair value (level 2)	25,850	25,850	39,207	39,207
Trade accounts receivable	Amortized cost	435,552	(*)	441,540	(*)
Judicial deposit	Amortized cost	22,399	(*)	22,571	(*)
Sales of ownership interest	Amortized cost	10,308	(*)	10,051	(*)
Indemnity assets	Amortized cost	20,427	(*)	9,426	(*)
Related parties	Amortized cost	1,101,247	(*)	1,095,803	(*)
		2,580,011		2,887,442	-
Financial liabilities					
Suppliers	Amortized cost	189,554	(*)	154,966	(*)
Loans and financing	Amortized cost	206,498	205,308	445,675	404,675
Loans and financing	Fair value (level 2)	1,658,063	1,533,019	1,526,864	1,548,482
Debentures	Amortized cost	1,812,835	1,516,309	1,764,427	1,505,116
Derivative instruments	Fair value (level 2)	90,829	90,829	107,046	107,046
Partnerships	Amortized cost	322	(*)	313	(*)
Redemption of shares	Amortized cost	113	(*)	113	(*)
Exclusivity right	Amortized cost	4,733	(*)	4,990	(*)
Dana Farber	Amortized cost	53,972	(*)	58,806	(*)
Related parties	Amortized cost	470,097	(*)	538,416	(*)
Accounts payable for acquisitions	Fair value (level 3)	59,745	59,745	58,924	58,924
Accounts payable for acquisitions	Amortized cost	23,748	(*)	43,449	(*)
		4,570,509	-	4,703,989	-
Financial instruments	Measurement	Consolidated			
		Book value	Fair value	Book value	Fair value
		03/31/2025	03/31/2025	12/31/2024	12/31/2024
Financial assets					
Cash and cash equivalents	Amortized cost	550,519	(*)	550,744	(*)
Securities	Amortized cost	1,107,895	(*)	1,467,551	(*)
Derivative instruments	Fair value (level 2)	25,850	25,850	39,207	39,207
Trade accounts receivable	Amortized cost	2,493,204	(*)	2,434,594	(*)
Judicial deposit	Amortized cost	70,325	(*)	66,165	(*)
Sales of ownership interest	Amortized cost	11,216	(*)	10,975	(*)
Indemnity assets	Fair value (level 2)	46,885	(*)	50,084	(*)
Related parties	Amortized cost	20,514	(*)	20,664	(*)
		4,326,407	-	4,639,984	-
Financial liabilities					
Suppliers	Amortized cost	994,297	(*)	1,019,530	(*)
Loans and financing	Amortized cost	469,162	660,536	942,235	880,157
Loans and financing	Fair value (level 2)	1,864,560	1,533,019	1,526,864	1,548,482
Derivative instruments	Fair value (level 2)	90,829	90,829	107,046	107,046
Debentures	Amortized cost	869,934	840,516	1,674,881	1,320,906
Debentures	Amortized cost	1,622,831	1,336,972	773,227	845,148
Partnerships	Amortized cost	32,857	(*)	34,420	(*)
Redemption of shares	Amortized cost	7,766	(*)	11,289	(*)
Accounts payable for acquisitions	Amortized cost	210,246	(*)	227,500	(*)
Accounts payable for acquisitions	Fair value (level 3)	205,944	205,944	205,474	205,474
Exclusivity right	Amortized cost	27,247	(*)	29,502	(*)
Dana Farber	Amortized cost	53,972	(*)	58,806	(*)
Related parties	Amortized cost	6,670	(*)	43,615	(*)
		6,456,315	-	6,654,389	-

(*) Except for the related-party balances, whose nature and conditions are disclosed in Note 28, and the

loans, debentures and financing, the Company's Management believes that the book values of the financial assets and financial liabilities measured at amortized cost approximate their respective fair values, considering that they are adjusted by provision, present values and/or adjusted by floating market rates.

29. RELATED PARTIES

Transactions between related parties were carried out in accordance with the conditions agreed between the parties. They are mainly comprised of accounts receivable from shareholders, dividends receivable and payable, loans receivable and payable with related companies and advances for future capital increase:

i) Transfer of funds among Group's companies (loans): Management transfers funds between group's companies. Balances are partially eliminated in the consolidated and mostly adjusted by the CDI. These balances are mostly adjusted by the CDI. The remaining balance in consolidated refers to noncontrolling shareholders and has an average maturity of two years.

ii) Apportionments: refers mainly to centralized shared services provided by the Parent Company, such as financial services (accounts receivable and accounts payable), accounting, legal, treasury, supplies, etc., which are shared among the other Group entities based on apportionment criteria that take into account the contribution of each entity for the Group's operations. Payments are made on a monthly basis and are not adjusted. These balances are substantially eliminated in the Consolidated Financial Information.

iii) Special Tax Regularization Program (PERT): Management decided to use part of the tax loss and negative basis of social contribution accumulated and declared by the parent company to settle the remaining balance of the consolidated debts, transferring the credits included in the program to subsidiaries of the same economic group. The deadline for realization of the balance is the ratification of credits and debits by the Brazilian Federal Revenue Service. These balances are eliminated in the Consolidated Financial Information.

29.1 Related parties (Assets)

	Parent Company		Consolidated	
	03/31/2025	12/31/2024	03/31/2025	12/31/2024
Loans (i)				
Related companies:				
Centro Paulista de Oncologia S.A. (i.b)	6,302	11,006	973	973
Núcleo de Oncologia da Bahia (NOB) (i.a)	96,903	100,599	-	-
Cruz Participações Ltda (Talassa) (i.b)	3	2,191	-	-
Centro Mineiro de Infusões S.A. (i.b)	1,000	1,000	-	-
Central de Gestão e Saúde Ltda (i.b)	973	939	-	-
Núcleo de Hematologia e Transplante Óssea de MG (i.b)	111	111	111	111
Hospital Marcos Moraes (i.b)	102,560	94,762	-	-
Radioterapia Oncoclínicas Rio de Janeiro Ltda. (i.b)	5,415	4,477	-	-
Núcleo de Oncologia de Sergipe S.A. (i.b)	-	1,679	-	-
Oncoclínicas Rio de Janeiro S.A. – CTTB (i.b)	60,982	73,206	-	-
Ira Instituto Roberto Alvarenga Ltda. (i.b)	8,568	8,310	-	-
Complexo Hospitalar Uberlândia S.A. (i.b)	170,148	137,973	-	-
UMC Imagem Ltda. (i.b)	8,341	8,055	-	-
Itaigara Memorial Hospital Dia Ltda. (i.b)	5,504	2,305	-	-
Instituto Oncoclínicas de Ensino (i.c)	13,058	13,840	13,058	13,840
CLION – Clínica de Oncologia Ltda. (i.b)	-	-	-	-
CAM – Clínica de Assistência à Mulher Ltda. (i.b)	37,340	36,064	-	-
Instituto de Câncer de Brasília Ltda (i.b)	14,913	23,843	-	-
Centro de Tratamento de Câncer de Brasília S.A. (i.b)	9,831	27,065	-	-
Imunomed Clínica de Infusão e Especialidades S.A. (i.b)	1,765	1,707	-	-
Idengene Medicina Diagnóstica S.A. (i.b)	-	2,378	-	-
Centro de Tratamento Radioterápico de Anápolis Ltda (i.b)	240	232	-	-
Onco Vida Instituto Especializado de Oncologia S.A. (i.b)	24,259	29,195	-	-
Hematológica - Clínica de Hematologia S.A. (i.b)	12,578	12,146	-	-
Onkos Oncologia Participações Ltda. (i.b)	-	539	-	-

	Parent Company		Consolidated	
	03/31/2025	12/31/2024	03/31/2025	12/31/2024
Talia Participações Ltda. (i.b)	8	4	-	-
CTC Oncologia S.A. (i.b)	769	583	-	-
Leste Fluminense S.A. (i.b)	122,368	92,303	-	-
Instituto do Coração do Triangulo Mineiro Ltda. (i.b)	2,025	1,658	-	-
Centro Brasileiro de Radioterapia Oncologia e Mastologia Cebrom Ltda (i.b)	20,520	29,702	-	-
Cardiomobile Cardiologia Móvel Ltda. (i.b)	950	916	-	-
CTR Centro de Tratamento em Radioterapia Ltda. (i.b)	1,303	859	-	-
Unity Participações S.A. (i.b)	572	551	-	-
Instituto Unity de Ensino e Pesquisa (i.b)	-	-	64	61
Aliança Instituto De Oncologia Ltda. (i.b)	12,764	12,347	-	-
Radiogroup Participações S.A. (i.b)	11	11	-	-
Ultraimagem Ltda. (i.b)	788	760	-	-
Clínica Ressonance Ltda. (i.b)	381	2,301	-	-
Yukon Oncologia E Participacoes S.A. (i.b)	138	5,064	-	-
Locus Anatomia Patologica e Citologia Ltda. (i.b)	-	1,750	-	-
Microimagem Lab de Anatomia Pat e Citopatologia Sc Ltda. (i.b)	-	1,176	-	-
Centro Mineiro De Infusões S.A. (i.b)	1,053	1,014	-	-
Gmn Grupo De Medicina Nuclear Ltda (i.b)	370	357	-	-
Giordani Camicia Servicos Medicos Ltda. (i.b)	108	103	-	-
Oncologia Manaus (i.b)	10	10	-	-
Masto Clinica de Mastologia da Bahia S.A.(i.b)	1,279	637	-	-
Instituto Sensumed de Ensino e Pesquisa (i.b)	-	-	51	51
Medsir Médica Scientia Innovation Resear (ib)	-	552	6,256	5,628
Total loans (a)	746,211	746,280	20,513	20,664

	Parent Company		Consolidated	
	03/31/2025	12/31/2024	03/31/2025	12/31/2024
Apportionments (ii)				
Shared service center	319,436	317,110	-	-
Work Project Units	13,642	13,436	-	-
Other (i.d)	21,958	17,324	-	-
Total apportionments (b)	355,036	347,870	-	-

	Parent Company		Consolidated	
	03/31/2025	12/31/2024	03/31/2025	12/31/2024
Related companies:				
Núcleo de Oncologia de Sergipe S.A.	-	107	-	-
Radioterapia Botafogo S.A.	-	267	-	-
Centro de Quimioterapia Oncoclínicas S.A.	-	241	-	-
Centro Capixaba de Oncologia S.A.	-	80	-	-
Hematológica Clínica de Hematologia S.A.	-	958	-	-
Total PERT (c)	-	1,653	-	-
Total (a) + (b) + (c)	1,101,247	1,095,803	20,513	20,664

i.a. Refers to loan operations and private debentures with Núcleo de Oncologia da Bahia S.A. (NOB), which are restated monthly by the CDI rate. Loan contracts have an average term of two (2) years and can be settled before maturity.

i.b. Refers to loan operations between the Company and its direct and indirect investees, which are monthly restated by the CDI + 1.9% p.a. with an average maturity of two (2) years.

i.c. Refers to loan operations between the Company and Instituto de Pesquisa Oncoclínicas, which are monthly restated by the CDI + 1.9% p.a. with an average maturity of two (2) years.

i.d. Refers to the transfer of expenses between Oncoclínicas and its direct and indirect investees.

29.2 Dividends receivable - Parent company

	Parent Company	
	03/31/2025	12/31/2024
Related companies:		
Radioterapia Botafogo S.A.	467	467
Centro Paulista de Oncologia S.A.	4,964	4,964
Centro Mineiro de Infusões S.A.	10,870	10,870
Oncoclínicas Salvador S.A.	352	352
Centro de Tratamento Oncológico S.A.	4,476	4,476
Oncocentro Imagem Serviços Médicos Ltda.	3,288	3,288
Instituto de Oncologia Ribeirão Preto S.A.	2	2
Hematológica – Clínica de Hematologia S.A.	4,342	4,342
Centro Brasileiro de Radioterapia Oncologia e Mastologia - CEBROM Ltda.	2,418	2,418
Navarra RJ (Leste Fluminense S.A.)	36,199	36,199
CPO – Centro Paraibano de Oncologia S.A.	465	465
Onco Vida Instituto Especializado de Oncologia Ltda	5,987	5,987
Aliança Instituto de Oncologia Ltda	1,117	1,117
Radiocare Serviços Médicos Especializadas Ltda.	5,219	5,219
Núcleo de Oncologia da Bahia S.A.	142	142
CTC Oncologia S.A.	1,002	1,002
AIO – Instituto de Câncer de Brasília Ltda	1,049	-
Unity Participações S.A.	14,826	14,826
Cettro – Centro de Tratamento Oncológico Ltda.	876	-
Talassa Oncologia e Participações S.A.	98	98
Ceu De Brasília Participações S.A.	-	5,768
Total	98,159	102,002

29.3 Advance for future capital increase (Assets)

	Parent Company	
	03/31/2025	12/31/2024
Related companies:		
Centro Mineiro de Infusões S.A.	5,888	601
Idengene Medicina Diagnóstica S.A.	-	2,500
Centro Oncológico e Tratamentos Especiais Ltda – COTE	-	1,250
Centro Paulista de Oncologia S.A.	28,315	40,000
Núcleo de Oncologia da Bahia S.A.	-	20,038
Pontus Participações S.A.	15,819	9,034
CTC Oncologia S.A.	21	21
Unity Participações S.A.	18,950	-
CTR - Centro de Tratamento Radioterápico de Anápolis Ltda.	5,156	5,156
Locus Anatomia Patologica E Citologia Ltda.	343	-
Andromeda Participações Ltda.	-	6,620
Talia Participações Ltda	100	899
Radioterapia Botafogo S.A.	-	370
Oc Franquias Ltda	100	-
Núcleo de Hematologia e Transplante de Medula Óssea de Minas Gerais Ltda.	-	750
Total	74,692	87,239

29.4 Related parties (Liabilities)

	Parent Company		Consolidated	
	03/31/2025	12/31/2024	03/31/2025	12/31/2024
Loans				
Unity Participações S.A.	6,113	-		
Multihemo Serviços Médicos S.A. (i)	111,610	107,931	-	-
Centro Paulista de Oncologia S.A.	21,711	20,919	-	-
Hospital Oncologia Meier S.A.	23	23	-	-
Hematológica Clínica de Hematologia S.A.	24	12,328	-	-
Centro Paraibano de Oncologia S.A.	-	16,954	-	-
Corp Centro de Oncologia de Rio Preto S.A.	16,095	15,528	-	-
Angará Participações S.A.	10,147	9,788	-	-
Clínica de Radioterapia e Quimioterapia de Presidente Prudente S.A.	8,525	8,213	-	-
Instituto de Radioterapia Vitória S.A.	6,166	5,948	-	-
Talassa Oncologia e Participações S.A.	-	5,133	-	-
Oncohematologia Participações Ltda.	4,293	4,142	-	-
Serviço de Atendimento Médico e Diagnóstico Ltda.	4,289	4,138	-	-
Centro Pernambucano de Oncologia S.A.	4,294	4,137	-	-
Imunomed Especialidades e Clínica de Infusão	4,093	3,951	-	-
Radioterapia Oncoclínicas Recife Ltda	3,037	2,926	-	-
Instituto de Hematologia e Oncologia Curitiba Clínica Medica S.A.	-	3,306	-	-
Other liabilities				
Specialized Medical Treatment Company	-	35,785	-	35,785
Núcleo de Oncologia da Bahia S.A. (iii)	23,361	34,219	-	-
Cruz Participações Ltda (Talassa Participações S.A.) (iii)	7,653	11,176	-	-
Navarra RJ (Leste Fluminense S.A.) (iii)	124	1,441	-	-
Hematologica Clinica de Hematologia S.A.	1,752	1,371	-	-
Núcleo de Hematologia e Transplante Óssea de MG	840	283	-	-
Oncoclínicas Centro De Tratamento Oncológico (iv)	211,271	210,861	-	-
Centro Mineiro De Infusões S.A.	10	10	-	-
SCP operation	8,148	7,912	-	-
Centro De Tratamento Em Radioterapia Ltda.	27	27	-	-
COT - Centro Oncológico do Triângulo S.A.	358	358	-	-
COT - Radioterapia Ltda	69	69	-	-
Reuma Centro de Reumatologia Avançada Ltda (ii)	-	-	1,173	2,333
DMS Participações e Administração Ltda (ii)	-	-	2,428	2,428
Sinapse Serviços Médicos Ltda. (ii)	-	-	3,024	3,024
Tiago Giordani Camicia	-	-	45	45
Oncoclínicas Rio De Janeiro S.A.	12,230	6,991	-	-
Apportionments payable	3,681	2,549	-	-
Total	470,097	538,417	6,670	43,615
Current	-	35,785	-	35,785
Non-current	470,097	502,631	6,670	7,830

i. Refers to the loan operation with the subsidiary Multihemo Serviços Médicos S.A., restated by interest of 100% of the CDI + 1.9% p.a., maturing in July 2026.

ii. It refers to operations for the transfer of dividends to participating partners who are not part of the Oncoclínicas Group's corporate structure.

iii. This refers to the obligation that the company assumed with its subsidiaries Talassa Participações S.A. and Navarra RJ (Leste Fluminense S.A.). to cover the redemption of shares from non-controlling

shareholders. It also includes the obligation to pay in capital to Núcleo de Oncologia da Bahia S.A.

iv. Refers to certain balances payable to its subsidiary, Oncoclínicas Centro de Tratamento Oncológico, arising from the settlement of obligations transferred in the corporate restructuring operation.

Income (loss) from related party transactions	Parent Company		Consolidated	
	03/31/2025	03/31/2024	03/31/2025	03/31/2024
Revenue				
Interest on loan	25,229	13,733	823	221
Expense				
Interest on loan	(6,654)	(7,406)	-	(565)
Apportionment of expenses	102,473	97,955	-	-
Costs of services rendered (i.e)	(760)	(962)	(2,757)	(2,277)

(i.e) Additionally, the Group entered into service agreements with companies held by some of its administrators in the amount whose object is the provision of specific and determined medical services in one or more specialties among those developed by the professional in question, including the performance medical appointments, diagnoses, prescription and follow-up of treatments at the Company's facilities and/or partners defined by the Company.

29.5 Dividends payable

	Consolidated	
	03/31/2025	12/31/2024
Multihemo Serviços Médicos S.A.	1,928	1,928
Núcleo de Oncologia da Bahia S.A.	249	248
Onco Vida Instituto Especializado de Oncologia Clínica S.A.	153	153
Núcleo de Oncologia de Sergipe S.A. (NOS)	844	844
Pro Onco Centro de Tratamento Oncológico S.A.	98	98
Aliança Instituto de Oncologia S.A.	16,407	19,263
Navarra RJ (Leste Fluminense S.A.)	6,230	6,230
Angará Participações S.A.	2,447	2,447
Yukon Participações S.A.	1,493	1,493
Instituto de Oncologia de Ribeirão Preto S.A.	7	7
COT - Centro Oncológico do Triângulo S.A.	906	906
Baikal Participações S.A.	2,055	2,055
Instituto de Hematologia e Oncologia de Curitiba S.A. – Clínica Médica	148	148
CECON – Centro Capixaba de Oncologia S.A.	123	123
CTC Oncologia S.A.	1,002	1,002
Centro Paulista De Oncologia S.A.	1	1
Hematológica - Clínica de Hematologia S.A.	51	51
Radiogroup Participações S.A.	38	39
Talassa Oncologia e Participações S.A.	98	98
Total	34,278	37,134

29.6 Advance for future capital increase (Liabilities)

	Consolidated	
	03/31/2025	12/31/2024
Subsidiaries:		
Onco Vida Instituto Especializado de Oncologia Clínica S.A.	2,492	2,492
Complexo Hospitalar Uberlândia S.A.	1,481	1,481
CTR - Centro de Tratamento Radioterápico de Anápolis Ltda	2,361	2,361
Total	6,334	6,334

29.7 Management remuneration

Key management personnel are the people who have authority and responsibility for planning, directing and controlling the Group's activities, directly or indirectly, including any director (executive or board).

During the year ended March 31, 2025, management remuneration was R\$ 6,540 (R\$ 25,996 in March 2024) for short-term benefits, such as salaries, charges and other. As long-term benefits, the Company recognized expenses related to the Stock Options program totaling R\$ 2,156 (R\$ 4,079 on March 31, 2024). There are no other benefits granted to administrators, such as: (a) post-employment benefits (pensions, other retirement benefits, post-employment life insurance and medical care); (b) long-term benefits (license for years of service and long-term disability benefits); (c) benefits on termination of employment contract.

30.INSURANCE

The Company has insurance coverage due to the risks existing in its operations. The policy is made directly by Oncoclínicas, and the premiums and risks are covered for the Company as mentioned in the policy.

The risk and type of insurance are mentioned below, and the amounts and coverage cover the full Oncoclínicas Group.

Modality	Coverage	Effectiveness
Civil liability	R\$10,000	12/14/2025
Administrative Liability D&O	R\$ 100,000	07/06/2025
E&O professional liability	R\$ 30,000	12/18/2025
Equity	R\$ 1,729,790	12/31/2025

31. TRANSACTIONS NOT AFFECTING CASH

	Note	Parent Company		Consolidated	
		03/31/2025	03/31/2024	03/31/2025	03/31/2024
Changes in accounts receivable	6	5,988	22,662	59,009	274,733
Non-cash effect					
Formation (reversal) of allowance for doubtful accounts and disallowance	6	(4,896)	3,667	65,144	61,882
Accounts receivable acquired by merger	1	273	-	-	-
Total of changes, less non-cash transactions of accounts receivable		1,365	26,329	124,153	336,615
Statement of cash flow		1,365	26,329	124,153	336,615
	Note	Parent Company		Consolidated	
		03/31/2025	03/31/2024	03/31/2025	03/31/2024
Changes in balance of dividends receivable		(3,845)	-	-	-
Non-cash effect					
Transfer of dividends receivable to the investment account	10	5,769	-	-	-
Dividends acquired by merger	1	(1,924)	-	-	-
Total of changes, less non-cash transactions of dividends receivable.		-	-	-	-
Statement of cash flow		-	-	-	-
	Note	Parent Company		Consolidated	
		03/31/2025	03/31/2024	03/31/2025	03/31/2024
Changes in property, plant and equipment		8,740	628	(11,283)	49,955
Changes in intangible assets		2,830	2,859	(15,124)	273,194
Total change in property, plant and equipment and intangible assets		11,570	3,487	(26,407)	323,149
Depreciation of property, plant and equipment	12	5,767	3,584	27,436	24,222
Amortization of intangible assets	13	14,020	16,232	27,929	36,517

	Note	Parent Company		Consolidated	
		03/31/2025	03/31/2024	03/31/2025	03/31/2024
Write-off of property, plant and equipment and intangible assets	12	-	-	2,034	21
Non-cash effect					
Machinery and equipment acquired in installments		-	-	8,612	(35,456)
Property, plant and equipment and intangible assets acquired through merger		(16,862)	-	-	-
Intangible assets and exclusivity right payable		-	-	-	(355)
Intangible assets - partnership		-	-	-	(294,896)
Interest capitalization		-	-	(156)	(1,402)
Exchange-rate change		-	-	-	(999)
Total of changes, less non-cash transactions of property, plant and equipment and intangible assets		14,495	23,303	39,448	50,801
Statement of cash flow					
Acquisition of property, plant and equipment	12	2,563	3,239	26,620	22,106
Acquisition of intangible assets	13	11,932	20,064	12,828	28,695
Total acquisitions of property, plant and equipment and intangible assets		14,495	23,303	39,448	50,801
Advance for future capital increase – ASSETS	Note	03/31/2025	03/31/2024	03/31/2025	03/31/2024
Change in balance of advance for future capital increase - Assets		(12,547)	(81,115)	-	-
Non-cash effect					
Advance for future capital increase (“AFAC”) transfer for capital increase in investment	10	140,768	134,026	-	-
Total advance for future capital interest non-cash transaction carried out		128,221	52,911	-	-
Statement of cash flow		128,221	52,911	-	-
Change in balance of Contingency	Note	03/31/2025	03/31/2024	03/31/2025	03/31/2024
		(344)	187	(1,603)	(769)

		Parent Company		Consolidated	
	Note	03/31/2025	03/31/2024	03/31/2025	03/31/2024
Non-cash effect					
Restatement of business combination indemnifiable asset	21	-	(142)	(1,343)	1,047
Total contingencies with effect on income (loss)		(344)	45	(2,946)	278
		Parent Company		Consolidated	
		03/31/2025	03/31/2024	03/31/2025	03/31/2024
Change in the balance of acquisitions					
Interest incurred	25	(211)	(2,174)	(4,990)	(10,618)
APV and FVA	25	(2,484)	(772)	(2,945)	(2,950)
Exchange-rate change		-	-	56	-
Discounts obtained		-	-	321	-
Non-cash effect					
Consideration assumed for merger		-	(10)	-	(302,370)
Total non-cash transaction of Acquisitions		(21,575)	(20,350)	(24,342)	(172,941)
Statement of cash flow					
Payment of charges	19	-	-	(3,337)	(2,732)
Payment of acquisitions on credit	19	(10,335)	(20,350)	(21,005)	(28,209)
Acquisitions of partnerships		-	-	-	(142,000)
Payment of acquisitions via credit granting	19	(11,240)	-	-	-
Total acquisitions with effect on the result according to the CFS		(21,575)	(20,350)	(24,342)	(172,941)